Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility

array:22 ["pii" => "S0034745022000622" "issn" => "00347450" "doi" => "10.1016/j.rcp.2022.06.001" "estado" => "S200" "fechaPublicacion" => "2022-08-03" "aid" => "552" "copyright" => "Asociación Colombiana de Psiquiatría" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S0034745022000853" "issn" => "00347450" "doi" => "10.1016/j.rcp.2022.07.005" "estado" => "S200" "fechaPublicacion" => "2022-09-03" "aid" => "560" "copyright" => "Asociación Colombiana de Psiquiatría" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Artículo original" "titulo" => "Prevalencia y factores del trastorno de conducta alimentaria en estudiantes de medicina humana del perú en el contexto de la pandemia de covid-19: estudio multicéntrico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Prevalence and Factors Associated with Eating Disorders in Peruvian Human Medicine Students in the Context of the COVID-19 Pandemic: a Multicentre Study" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jean Pierre Zila-Velasque, Pamela Grados-Espinoza, Kateriny Margot Regalado-Rodríguez, Cesia J. Luna-Córdova, Gabriela Stefanie Sierra Calderón, Mills Díaz-Vargas, Jhesly Sifuentes-Rosales, Cristian Diaz-Vélez" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Jean Pierre" "apellidos" => "Zila-Velasque" ] 1 => array:2 [ "nombre" => "Pamela" "apellidos" => "Grados-Espinoza" ] 2 => array:2 [ "nombre" => "Kateriny Margot" "apellidos" => "Regalado-Rodríguez" ] 3 => array:2 [ "nombre" => "Cesia J." "apellidos" => "Luna-Córdova" ] 4 => array:2 [ "nombre" => "Gabriela Stefanie Sierra" "apellidos" => "Calderón" ] 5 => array:2 [ "nombre" => "Mills" "apellidos" => "Díaz-Vargas" ] 6 => array:2 [ "nombre" => "Jhesly" "apellidos" => "Sifuentes-Rosales" ] 7 => array:2 [ "nombre" => "Cristian" "apellidos" => "Diaz-Vélez" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745022000853?idApp=UINPBA00004N" "url" => "/00347450/unassign/S0034745022000853/v1_202209030512/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0034745017300045" "issn" => "00347450" "doi" => "10.1016/j.rcp.2017.01.003" "estado" => "S200" "fechaPublicacion" => "2017-02-24" "aid" => "196" "copyright" => "Asociación Colombiana de Psiquiatría" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "Artículo de revisión" "titulo" => "Alteraciones endocrinas vinculadas a la prescripción médica de carbonato de litio. Una revisión narrativa" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Endocrinological Disorders Related to the Medical Use of Lithium. A Narrative Review" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1444 "Ancho" => 3179 "Tamanyo" => 221305 ] ] "descripcion" => array:1 [ "es" => "Línea del tiempo para estudios de laboratorio y gabinete<a class="elsevierStyleCrossRefs" href="#bib0745">49,50,79–81</a>. Litemia: 1.a al mes y trimestralmente las siguientes. A partir de 1.er año, semestrales. Estudios de laboratorio y gabinete: protocolos completos en cuadros superiores. 1.er año: perﬁl tiroideo y glucosa. 2.o año: ultrasonido tiroideo. 3.er año: protocolo similar al basal. En cualquier momento, realizar los estudios que sean necesarios en correlación con hallazgos clínicos. *Los números romanos corresponden a los meses del año." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Gerardo García-Maldonado, Rubén de Jesús Castro-García" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Gerardo" "apellidos" => "García-Maldonado" ] 1 => array:2 [ "nombre" => "Rubén de Jesús" "apellidos" => "Castro-García" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2530312018300602" "doi" => "10.1016/j.rcpeng.2018.12.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530312018300602?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745017300045?idApp=UINPBA00004N" "url" => "/00347450/unassign/S0034745017300045/v1_201702240102/es/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "Artículo original" "titulo" => "Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Oscar Ribero, Anne-Marie Castilloux, Lina Maria Agudelo, Gerardo Machnicki, Vanesa Morales, Sergio Perocco, Genaro Castillon, Yola Moride" "autores" => array:8 [ 0 => array:3 [ "nombre" => "Oscar" "apellidos" => "Ribero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Anne-Marie" "apellidos" => "Castilloux" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Lina Maria" "apellidos" => "Agudelo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Gerardo" "apellidos" => "Machnicki" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "Vanesa" "apellidos" => "Morales" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 5 => array:3 [ "nombre" => "Sergio" "apellidos" => "Perocco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 6 => array:3 [ "nombre" => "Genaro" "apellidos" => "Castillon" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 7 => array:4 [ "nombre" => "Yola" "apellidos" => "Moride" "email" => array:1 [ 0 => "morideyo@ifh.rutgers.edu" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "E.S.E. Hospital Mental de Antioquia, Bello, Antioquia, Colombia" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "YolaRX Consultants, Montreal, Quebec, Canada" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Janssen-Cilag Farmacéutica Ltda., Buenos Aires, Argentina" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Janssen-Cilag S.A., Bogotá, Colombia" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Janssen-Cilag Farmacêutica Ltda., São Paulo, Brazil" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States of America" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efectividad Del Palmitato de Paliperidona en la Adherencia al Tratamiento y Las Recaídas en la Población Adulta Con Esquizofrenia: Un estudio en Imagen Especular de un Año en un Centro de salud Mental en Colombia" ] ] "textoCompleto" => "IntroductionIn 2013, the Ministry of Health of Colombia reported a prevalence of schizophrenia of 1%, corresponding to about 471,052 people affected by the disease in this country.<a class="elsevierStyleCrossRef" href="#bib0125">1</a> Like elsewhere, prevalence is low but the disease results in a tremendous health, social, and economic burden linked to the early onset of the disease, its incurable nature as well as persisting symptoms.<a class="elsevierStyleCrossRef" href="#bib0130">2</a>Antipsychotics are the cornerstone treatment of schizophrenia with the aims of functional rehabilitation, prevention of symptom worsening, enhancement of psychosocial functioning, and improvement of quality of life.<a class="elsevierStyleCrossRef" href="#bib0135">3</a> However, non-adherence to oral antipsychotics (OAPs) ranges between 34% and 81%, which greatly affects their effectiveness in the real-world setting.<a class="elsevierStyleCrossRef" href="#bib0140">4</a> Despite a good response to initial treatment, schizophrenia symptoms often return, which are especially frequent after treatment discontinuation.<a class="elsevierStyleCrossRef" href="#bib0145">5</a> Consequently, the prevention of relapse is a primary treatment goal for the successful long-term management of schizophrenia.<a class="elsevierStyleCrossRef" href="#bib0150">6</a>Long-acting injectable (LAI) formulations have become available to enhance adherence and thereby improve outcomes. According to a meta-analysis of 10 randomized controlled trials (RCTs) published in 2011, LAIs are associated with a lower risk of relapse compared to OAPs (relative risk [RR]=0.70; 95% confidence interval [95%CI], 0.57-0.87).<a class="elsevierStyleCrossRef" href="#bib0155">7</a> Since then, the benefits of LAIs compared to OAPs have also been shown through observational studies, mainly those that use a mirror-image study design.<a class="elsevierStyleCrossRef" href="#bib0160">8</a> Paliperidone palmitate administered once monthly (PP1M) is one of the LAIs approved for the treatment of schizophrenia,<a class="elsevierStyleCrossRefs" href="#bib0165">9,10</a> and real-world studies have shown that PP1M is associated with significantly fewer inpatient admissions compared to OAPs, mainly due to improved treatment adherence.<a class="elsevierStyleCrossRefs" href="#bib0175">11–14</a> Because these previous studies have used hospitalization as a measure of relapse, effectiveness of PP1M on a broader manifestation of relapse, such as symptoms not leading to hospitalization, remains poorly examined. Furthermore, there is a paucity of data in the Latin American region on the characteristics of schizophrenia patients treated with PP1M and on its effectiveness on real-world outcomes in this setting.Our study aimed at evaluating the effectiveness of PP1M on treatment adherence and relapse in the adult schizophrenia population followed in a government-funded mental health care facility with a broad geographical coverage in Bello, Antioquia (Colombia).Materials and methodsStudy designWe conducted a single-arm, non-interventional pre-post comparison (“mirror-image”) study to describe the characteristics of adult patients with schizophrenia who initiated PP1M, and to compare treatment adherence and relapse before and after the PP1M initiation. Study was conducted in the inpatient and outpatient settings of E.S.E. Hospital Mental de Antioquia, a 250-bed facility situated in Bello (vicinity of Medellin), Colombia. There were two retrospective treatment phases: 12 months prior to the first injection of PP1M (pre-phase) and 12 months after the first injection (post-phase). The date of first injection was referred to as the index date. The study was approved by the research ethics committee at the E.S.E. Hospital Mental de Antioquia.Data sourcesThe main data source consisted of secondary use of existing electronic medical records (EMRs) at E.S.E. Hospital Mental de Antioquia. There are approximately 65,000 psychiatric consultations per year at this hospital, and it is estimated that medical records are available for approximately 25,000 psychiatric care patients of all ages.<a class="elsevierStyleCrossRef" href="#bib0195">15</a> Dispensed medications, including PP1M, OAPs, and concomitant drugs, were obtained through linkage with the hospital pharmacy database, which dispenses the totality of in- and out-patient psychiatric drugs to patients followed at the facility. We ascertained non-hospitalized relapse through the examination of physicians’ notes (narratives) found in the EMRs.Study populationWe identified the study population over the period January 1st, 2015 to October 31st, 2018 in order to have a 12-month pre- and a 12-month post-phase for all study patients (first pre-phase started January 1st, 2014 and last post-phase ended October 31st, 2019).We included patients who met the following inclusion criteria: a) a confirmed diagnosis of schizophrenia (ICD-10 codes: F20.0 [Paranoid schizophrenia], F20.1 [Disorganized schizophrenia], F20.2 [Catatonic schizophrenia], F20.3 [Undifferentiated schizophrenia], F20.5 [Residual schizophrenia], F20.6 [Simple schizophrenia], F20.8 [Other schizophrenia], and F20.9 [Schizophrenia, unspecified]) identified at least one year prior to index date; b) to have been prescribed an OAP treatment, regardless of treatment duration and number of products, in pre-phase; c) age ≥18 years (adult patients) at first injection of PP1M (index date); d) to have received an initial dose of ≥2 injections of PP1M in a period of one week, regardless of concomitant use of OAPs, treatment duration, and subsequent switches to other LAIs or switch back to OAPs only, and e) to have been followed at the E.S.E. Hospital Mental de Antioquia for at least 12 months prior to, and 12 months after the index date in order to ensure completeness of the EMR. We excluded patients who: a) were diagnosed with refractory schizophrenia; b) used LAIs in pre-phase; c) initiated PP1M in hospital and were never discharged during the following 12 months, and d) died or were lost to follow-up in the post-phase.OutcomesTreatment adherenceWe measured treatment adherence using the proportion of days covered (PDC), defined as the proportion of days with an active antipsychotic drug (total number of days supply) over the entire pre- and post-phase, with the removal of overlapping prescriptions.<a class="elsevierStyleCrossRef" href="#bib0200">16</a> This means that the number of days supply of a drug that is left at the time of switch to a new product is not counted in the PDC calculation. Furthermore, because schizophrenia requires continuous treatment, PDC was calculated in each phase using the entire 365 days as denominator. For OAPs, the total number of days supply was calculated using the dispensing dates and the number of days dispensed. Patient was considered adherent to treatment if PDC was ≥80%.<a class="elsevierStyleCrossRef" href="#bib0200">16</a> Because the risk of hospitalization increases with every missed day of OAP use,<a class="elsevierStyleCrossRef" href="#bib0205">17</a> no allowance (i.e., no grace period) was given to assess the number of days with active prescription for OAPs. In accordance with previous published studies, each injection of PP1M was associated with 45 days of active prescription.<a class="elsevierStyleCrossRefs" href="#bib0210">18,19</a> Because of the inclusion criterion of at least two injections in a period of one week, the PDC in the post-phase was calculated starting at 45 days following the second injection. We also conducted a sensitivity analysis, where PP1M was associated with 30 days of active prescription.Although hospital-supplied medication during inpatient stay is recorded in the hospital database, adherence is a measure of patient's behavior. Adherence to OAPs during hospitalization is expected to be 100% and would thus lead to an overestimation of the overall PDC during the 12-month period. Hence, for patients who were hospitalized, the number of days of inpatient stay was not considered for the PDC calculation (neither in the PDC's numerator or denominator).RelapseClinically, relapse is defined by the presence of at least one of the following criteria: a) involuntary or voluntary admission to a psychiatric hospital for decompensation of the patient's schizophrenic symptoms (psychiatric hospitalization or emergency department [ED] visit); b) suicidal/homicidal ideation judged clinically significant; c) deliberate self-injury; d) clinically meaningful worsening of symptoms as determined by the treating physician's judgment, and e) violent behavior resulting in clinically significant injury to the patient or another person, or property damage.<a class="elsevierStyleCrossRefs" href="#bib0220">20–24</a> Hence, we assessed relapse using objective measures of the composite variable of hospitalization or ED visit during the study period (pre- and post-phase) as well as hospital length of stay (LoS). In addition, we identified relapse symptoms (also referred to as “relapse signatures”) through a manual review of clinical notes. Those relapse symptoms not leading to hospitalization or ED visits were then categorized into four categories: suicidal/homicidal ideation; deliberate self-injury; clinically meaningful worsening of symptoms; violent behavior.We therefore derived five measures of relapse for each patient and for each phase: a) at least one hospitalized relapse (binary variable); b) number of hospitalized relapses (count); c) total hospital LoS; d) at least one occurrence of relapse symptoms not leading to hospitalization or ED visit (binary variable), and e) number of relapse symptoms not leading to hospitalization or ED visit (count).Potential confoundersSince patients served as their own reference, confounders that remain unchanged over time were controlled for by design. However, we considered as potential confounders variables that vary over time and that may influence the study outcomes —i.e., comorbidities, concomitant psychiatric illnesses, alcohol use, tobacco use, illicit drug use, psychosocial interventions, electroconvulsive therapy— and, for the outcomes of relapse symptoms not leading to hospitalization or ED visit, number of psychiatric outpatient visits (since there would be more opportunity for the detection of relapse symptoms).Statistical analysesComparison of treatment adherence and relapse between pre- and post-phaseWe conducted descriptive analyses on patient socio-demographic and clinical characteristics, schizophrenia subtype and number of years since diagnosis, pattern of OAP use in the pre-phase (number and name of OAP products), status of patient at PP1M initiation (inpatient or outpatient), reason for PP1M initiation, and discontinuation of PP1M during follow-up (switch to OAP only, or to another LAI with or without OAP). As these were descriptive analyses, there was no hypothesis-testing.We compared frequencies of treatment adherence, hospitalized relapse (dichotomous and count), total hospital LoS, and non-hospitalized relapse symptoms (dichotomous and count) between the pre- and post-phase. A McNemar test on discordant pairs between pre- and post-phase was used to assess the consistency in adherence, hospitalized relapse, and non-hospitalized relapse. Crude and multivariable conditional Poisson regression models were developed for these outcomes. Confounders that varied over time (described in subsection Potential confounders) were included in the multivariable analyses. We conducted subgroup analyses for patients who continued PP1M and for patients who discontinued (dropped out) during post-phase.To account for immortal time bias, we conducted a sensitivity analysis for the outcomes of hospitalized relapse and number of hospitalized relapses, whereby the index hospitalization was excluded from the pre-phase for patients who initiated PP1M in hospital.ResultsPatient identification flow chart<a class="elsevierStyleCrossRef" href="#sec0110">Figure 1 in the supplementary material</a> presents the patient selection flow chart for the study. A total of 372 adult patients initiated PP1M at E.S.E. Hospital Mental de Antioquia between January 1st, 2015 and October 31st, 2018, out of whom 123 (33.1%) were included in the study. Main reason for exclusion was LAI use in the pre-phase (n=180, 48.4%). There were 54 patients who were lost to follow-up, all for administrative issues such as change of contact information or moving to a different geographical area. There were no death and loss to follow-up was not attributable to treatment failure.Patient characteristicsAs shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>, most patients were young (mean age, 30.3 years) and males (n=98, 79.7%). The majority was diagnosed with paranoid schizophrenia (n=74, 60.2%), followed by other schizophrenia (i.e., ICD-10 code F20.8). Most patients initiated PP1M as outpatient (n=86, 69.9%) and poor adherence with OAPs was the primary reason for PP1M initiation for half the patients, followed by a lack of efficacy.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Treatment characteristicsNumber and types of OAP used during pre- and post-phase are shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>. As expected, mean number of OAP products use was higher in the pre-phase than in the post-phase, since it was an inclusion criterion for the study. The most common prescribed OAPs in pre-phase were risperidone and olanzapine while in the post-phase, it was clozapine and olanzapine.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Discontinuation of PP1M occurred in 48 patients (39.0%), on average 6 months after initiation. A minority switched to another LAI (pipotiazine palmitate [n=6] and risperidone [n=4]), with or without use of OAPs, while 29 (60.4%) switched to OAPs only. Details are shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>. The number of patients who discontinued PP1M did not increase in the sensitivity analysis when considering 30 days of active treatment instead of 45.<elsevierMultimedia ident="tbl0015"></elsevierMultimedia>Outcomes<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a> presents the number of patients with outcomes in pre- and post-phase. More patients were adherent in the post-phase than in the pre-phase, 110 (89.4%) vs 29 (23.6%). Results remained the same, whether the number of days of active prescription assigned to each PP1M injection was 45 or 30 in the sensitivity analysis. McNemar test, which tests difference in discordant pre-post pairs, was statistically significant (P<0.0001). The number of patients with at least one hospitalized relapse decreased from 57 (46.3%) in pre-phase to 43 (35.0%) in post-phase. McNemar test was statistically significant (P=0.0433). The only relapse symptom not leading to hospitalization or ED visit reported for this study was “clinically meaningful worsening of symptoms”. The number of patients reported as having had this symptom increased in post-phase. McNemar test was statistically significant (P=0.0039).<elsevierMultimedia ident="tbl0020"></elsevierMultimedia>As shown in <a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>, the mean number of hospitalized relapses decreased from 0.89± 1.21 in pre-phase to 0.54±0.93 in post-phase (P=0.0012), while total hospital LoS decreased from 12.2 to 11.4 days (P=0.7713). Conversely, the mean number of non-hospitalized relapse increased from 0.07±0.29 to 0.25±0.61 (P=0.0013).<elsevierMultimedia ident="tbl0025"></elsevierMultimedia>Adjusted relative risks based on conditional Poisson regression, along with 95%CIs, are presented in <a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a> for each outcome. Only potential confounders that changed between pre- and post-phase (i.e., illicit substance use and number of psychosocial interventions) were included in the multivariable model and interaction was tested between all variables of the model. In addition, for the outcome of relapse symptoms not leading to hospitalization or ED visit, the number of outpatient medical visits was added to the multivariable model. The sensitivity analysis, whereby the index hospitalization was excluded from the pre-phase for those who started PP1M as inpatients, is also presented for the outcomes of hospitalized relapse, number of hospitalized relapses and hospital total LoS.<elsevierMultimedia ident="tbl0030"></elsevierMultimedia>Probability of being adherent to any antipsychotic treatment in post-phase was 3.77 times higher than in pre-phase (95% CI, 2.75-5.17). This probability was similar for patients who continued and for patients who discontinued PP1M in post-phase, as adherence was determined for all treatments combined (PP1M and/or OAPs). The risk of hospitalized relapse (RR=0.76; 95% CI, 0.59-0.99) and the number of hospitalized relapses (RR=0.61; 95% CI, 0.45-0.83) decreased in post-phase. These decreases were greater in patients who continued PP1M (RR=0.64; 95% CI, 0.42-0.98; and RR=0.52; 95% CI, 0.33-0.83 respectively) and not significant for patients who discontinued PP1M (RR=0.91; 95% CI, 0.65-1.25; and RR=0.67; 95% CI, 0.44-1.03 respectively). In contrast, the risk of relapse symptoms and the number of relapse symptoms increased in post-phase (RR=2.27; 95% CI, 1.11-4.64; and RR=2.51; 95% CI, 1.16-5.40 respectively), and these increases were more important for patients who discontinued PP1M (RR=3.33; 95% CI, 0.95-11.70; and RR=3.95; 95% CI, 1.25-12.48, respectively for relapse symptoms and number of relapse symptoms) than for patients who continued PP1M (RR=2.15; 95%CI, 0.79-5.81; and RR=2.18; 95% CI, 0.77-6.20, respectively for relapse symptoms and number of relapse symptoms).In the sensitivity analyses, when removing the index hospitalization for patients who started PP1M as inpatients, the risk of hospitalized relapse and the number of hospitalized relapses became statistically nonsignificant between pre- and post-phase (RR=1.05; 95% CI, 0.79-1.38; and RR=0.93; 95% CI, 0.67-1.29 respectively). The results were also statistically nonsignificant for patients who continued PP1M and for those who dropped out. Conversely, the mean hospital LoS in the pre-phase was 9.5 days decreasing to 6.0 days in the post phase (P=0.017).DiscussionIn this single center study, adherence to OAP prior to the initiation of PP1M was 23.6% using the threshold of 80% of the PDC, which is lower than estimates reported in the literature (34% to 81%).<a class="elsevierStyleCrossRef" href="#bib0140">4</a> However, this was to be expected due to the selection of the study population. As this was a mirror-image study, by design all patients initiated PP1M and it was shown that half of these patients initiated PP1M because of poor adherence to OAP. Similar to previous mirror-image studies, PP1M initiation significantly improved treatment adherence. It can therefore be concluded that in patients who are not adherent to OAPs, PP1M initiation greatly improves adherence over a period of one year, even if some patients discontinue the product.Initiation of PP1M was associated with a RR of 0.76 for hospitalized relapse. Such protective effect is lower than that found in a meta-analysis of six observational studies that included the LAI dropouts (RR=0.44; 95%CI, 0.28-0.67).<a class="elsevierStyleCrossRef" href="#bib0160">8</a> However, in this meta-analysis, estimates were pooled even in the presence of very high statistical heterogeneity between studies (I2>90%). The magnitude of the reduction in hospitalized relapse found in the current study is nearly the same as that found in a meta-analysis of RCTs (RR=0.7).<a class="elsevierStyleCrossRef" href="#bib0155">7</a> Several studies found in the literature were based on administrative claims data (where symptoms are not documented) while in the hospital EMRs, reasons for hospitalizations are very well documented. Quality of outcome ascertainment may partly explain some of the discrepancies between the effect size found in the current study with those of previous observational studies.Initiation of PP1M also led to a decrease in the number of hospitalized relapse episodes with a RR of 0.61 (95% CI, 0.45-0.83). This protective effect is lower than the one previously reported in the meta-analysis of five observational studies that included the LAI dropouts, although it is within the 95% CI of the published estimate (RR=0.42; 95% CI, 0.29-0.63).<a class="elsevierStyleCrossRef" href="#bib0160">8</a> In this meta-analysis, estimates were also pooled even in the presence of very important statistical heterogeneity (I2=93.5%). The beneficial effect of PP1M on the rate of hospitalization disappeared when removing the index hospitalization in the sensitivity analysis. Conversely, decrease in mean LoS became statistically significant. Previous studies have also shown that the removal of the index hospitalization not only affected hospitalization rate but also accentuated the beneficial effect of PP1M on total LoS. It was therefore suggested that PP1M would be more cost-effective when started in an outpatient setting.<a class="elsevierStyleCrossRef" href="#bib0180">12</a> To further elucidate this hypothesis, the effect of PP1M on hospitalization rate and LoS, stratification of findings according to initiation setting (inpatient or outpatient) would need to be conducted.Although it is known that treatment discontinuation is highly associated with the worsening of schizophrenia symptoms, there were no studies found in the literature that examined the effect of PP1M initiation on non-hospitalized relapse. Such data gap is mainly due to the absence of qualitative information on clinical symptoms in administrative claims databases. In contrast, symptoms worsening is well documented in the hospital EMRs. Study showed that PP1M initiation resulted in an increase in the proportion of patients with non-hospitalized relapse. This may partly be attributable to the fact that patients who are treated with PP1M must attend the clinic monthly to receive their injection at this hospital, which is accompanied by a medical follow-up visit. Such increase in regular follow-up visits, compared to pre-phase, increases the opportunity for the assessment of relapse symptoms and thus, introduce a detection bias (which is a form of information bias). It is also common that in time periods between changes in medication, especially antipsychotics, some patients could experience an exacerbation of symptoms of schizophrenia that are not severe enough to initiate hospitalized care.Comparing the effect of initiating PP1M on hospitalized and non-hospitalized relapse, one may thus conclude that avoided hospitalizations due to relapse may have contributed to the increase in relapses that were managed in the outpatient setting. Such impact is thus clinically meaningful.Generalizability of study results is limited to the population who receives mental health services at the E.S.E. Hospital Mental de Antioquia. The eligibility requirement of at least two PP1M injections may introduce selection bias because the start of follow-up predates eligibility. This is a period often labeled as “immortal time”. This period, however, was not included in the calculation of adherence. Because it was necessary to allow for a 12-month post-phase period, patients who died or were lost to follow-up during post-phase were not included, and hence, may have overestimated the benefits of PP1M. Nevertheless, loss to follow-up of 54 patients who initiated PP1M was due to administrative issues (e.g., change of contact information or, moved to a different geographical area). There were no deaths among these 54 patients. The removal of the index hospitalization in the sensitivity analysis removed the benefits of PP1M on hospitalization rates but accentuated the effect on LoS, which may suggest that the greatest benefits are observed in patients who started PP1M as outpatients. This hypothesis would, however, need further investigation using a larger sample size stratifying by inpatient and outpatient status at PP1M initiation. Due to the absence of a comparison group (i.e., non-PP1M initiators), it was not possible to differentiate relapses attributable to the initiation of PP1M from those attributable to the natural history of the disease.ConclusionsPP1M initiation led to a dramatic improvement in treatment adherence as well as to a decrease in the occurrence and number of hospitalized relapse episodes. Conversely, there was an increase in the management of relapse symptoms in the outpatient setting, even after taking into account detection bias. This increase could be explained by an improvement in the psychiatric follow-up after PP1M initiation. It is also common that in time periods between changes in medication, especially antipsychotics, some patients could experience an exacerbation of symptoms of schizophrenia that are not severe enough to initiate hospitalized care.FundingThis study was funded by McNeill Panama. The funding source was involved in the study design and in the decision to submit the article for publication. The funder had no role in the conduct of the study, i.e., patient selection, data collection, management, analyses, and interpretation of findings.Conflicts of interestsOR is a member of an advisory board and a speaker for Janssen on diseases unrelated to this study. AMC, GC, and YM are employees of YolaRX Consultants, which designed this study, conducted the statistical analyses, interpreted the results, and wrote the manuscript under contractual agreement. LMA has nothing to disclose. GM and VM were employees of Janssen at the time the research was conducted." "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1752720" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1543878" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1752721" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1543877" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Materials and methods" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study design" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Data sources" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Study population" ] 3 => array:3 [ "identificador" => "sec0030" "titulo" => "Outcomes" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Treatment adherence" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Relapse" ] ] ] 4 => array:2 [ "identificador" => "sec0045" "titulo" => "Potential confounders" ] 5 => array:3 [ "identificador" => "sec0050" "titulo" => "Statistical analyses" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0055" "titulo" => "Comparison of treatment adherence and relapse between pre- and post-phase" ] ] ] ] ] 6 => array:3 [ "identificador" => "sec0060" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Patient identification flow chart" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "Patient characteristics" ] 2 => array:2 [ "identificador" => "sec0075" "titulo" => "Treatment characteristics" ] 3 => array:2 [ "identificador" => "sec0080" "titulo" => "Outcomes" ] ] ] 7 => array:2 [ "identificador" => "sec0085" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0090" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0095" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0100" "titulo" => "Conflicts of interests" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-04-12" "fechaAceptado" => "2022-06-09" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1543878" "palabras" => array:5 [ 0 => "Antipsychotics" 1 => "Paliperidone palmitate" 2 => "Schizophrenia" 3 => "Adherence" 4 => "Relapse" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1543877" "palabras" => array:5 [ 0 => "Antipsicóticos" 1 => "Palmitato de paliperidona" 2 => "Esquizofrenia" 3 => "Adherencia" 4 => "Recaída" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "IntroductionThe benefits of long-acting injectable antipsychotics have been documented in several observational studies, but data remain scarce in Latin America. This study aimed at evaluating the effectiveness of paliperidone palmitate once monthly (PP1M) on treatment adherence and relapse in the schizophrenia population followed in a government-funded mental health care facility in Colombia. MethodsA mirror-image study was conducted. Adult schizophrenia patients treated with oral antipsychotics who subsequently received ≥2 PP1M injections between Jan. 1st, 2015 and Oct. 31st, 2018 were included. The study consisted of two retrospective phases: 12 months before and after the first PP1M injection. Outcomes were treatment adherence (proportion of days covered ≥80%), hospitalized relapse, hospital length of stay, and non-hospitalised relapse. Effect of PP1M on outcomes was assessed through multivariable conditional Poisson regression. Results123 patients were eligible (mean age, 30.3 years; 79.7% males). Adherence was 23.6% in the pre-phase and 89.4% in the post-phase (RR=3.77; 95%CI, 2.75-5.17). The proportion of patients with hospitalised relapse decreased from 46.3% to 35.0% (RR=0.76; 95%CI, 0.59-0.99). In the 75 (61.0%) patients who continued PP1M throughout post-phase, beneficial effect on hospitalised relapse was stronger (RR=0.64; 95%CI, 0.42-0.98). The proportion of patients with non-hospitalised relapse symptoms increased from 6.5% to 18.7% (RR=2.27; 95%CI, 1.11-4.64). ConclusionsPP1M initiation led to a dramatic improvement in treatment adherence and a decrease in hospitalised relapse. Observed increase in non-hospitalised relapse may be explained by a decrease in severity. Limitations are absence of a parallel comparison group and a generalisability limited to the population treated at this facility. Study provides data for the Latin America region and strength is the assessment of non-hospitalised relapse symptoms." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "IntroducciónLos beneficios de los antipsicóticos inyectables de acción prolongada se han documentado en varios estudios observacionales, pero los datos de América Latina siguen siendo escasos. El estudio se dirige a evaluar la efectividad del palmitato de paliperidona 1 vez al mes (PP1M) en la adherencia al tratamiento y las recaídas en la población con esquizofrenia seguida en un centro público de salud mental en Colombia. MétodosSe realizó un estudio en imagen especular. Se incluyó a pacientes adultos con esquizofrenia tratados con antipsicóticos orales que posteriormente recibieron> 2 PP1M entre el 1 de enero de 2015 y el 31 de octubre de 2018. El estudio consistió en 2 fases retrospectivas: 12 meses antes y después de la primera inyección de PP1M. Se evaluó la adherencia al tratamiento (proporción de días cubiertos ≥ 80%), la recaída hospitalizada, la duración de la estancia hospitalaria y la recaída no hospitalizada. El efecto del PP1M se evaluó mediante la regresión de Poisson. ResultadosFueron elegibles 123 pacientes (media de edad, 30,3 años; el 79,7% varones). La adherencia fue del 23,6% en la fase previa y del 89,4% en la segunda (RR=3,77; IC95%, 2,75-5,17). La proporción de pacientes con recaída hospitalizada disminuyó del 46,3 al 35,0% (RR=0,76; IC95%, 0,59-0,99). De los 75 pacientes (61,0%) que continuaron PP1M en la segunda fase, el efecto beneficioso en la recaída hospitalizada fue más fuerte (RR=0,64; IC95%, 0,42-0,98). La proporción de pacientes con síntomas de recaída no hospitalizados aumentó del 6,5 al 18,7% (RR=2,27; IC95%, 1,11-4,64). ConclusionesLa iniciación de PP1M llevó a una drástica mejora en la adherencia al tratamiento y a una disminución de la recaída hospitalizada. El aumento observado en la recaída no hospitalizada puede explicarse por una disminución de la gravedad. Las limitaciones son la ausencia de un grupo de comparación paralelo y que la generalizabilidad se limita a la población tratada en este centro. La fortaleza del estudio es la presentación de datos de la región de América Latina y la evaluación de síntomas de recaída no hospitalizada." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<elsevierMultimedia ident="upi0005"></elsevierMultimedia>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0110" ] ] ] ] "multimedia" => array:7 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "ICD-10: International Classification of Diseases 10th Revision; OAP: oral antipsychotic; PP1M: paliperidone palmitate once monthly; SD: standard deviation." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristic \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N=123 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age (years)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30.3 (10.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Min-Max \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18-60 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sex, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 (20.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">98 (79.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Schizophrenia ICD-10 subtype, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Paranoid schizophrenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">74 (60.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Other schizophrenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48 (39.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Residual schizophrenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (0.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patient status at PP1M initiation, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Outpatient \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">86 (69.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inpatient \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37 (30.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Primary reason for PP1M initiation, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adherence issue with OAPs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">62 (50.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lack of efficacy of OAPs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44 (35.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patient preference \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (5.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tolerance issue \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (4.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (3.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Patient socio-demographic and clinical characteristics, patient status at index date, and primary reason for PP1M initiation." ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "OAP: oral antipsychotic; SD: standard deviation." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N=123</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristic \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pre-phase \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Post-phase \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of OAP products use, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.8 (0.90) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.5 (0.83) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Min-Max \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Type of OAP use, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Risperidone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">68 (55.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">43 (35.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Olanzapine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">57 (46.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50 (40.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clozapine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40 (32.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51 (41.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Paliperidone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 (19.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (8.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 (27.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 (26.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "OAP treatment during pre- and post-phase." ] ] 2 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "LAI: long-acting injectable; OAP: oral antipsychotic; PP1M: paliperidone palmitate once monthly; SD: standard deviation." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PP1M discontinuation, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48 (39.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">75 (61.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Time to PP1M discontinuation (days)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">186.9 (113.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">147 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Min-Max \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53-360 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Switch back to OAP only, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29 (60.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 (39.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Switch to another LAI, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (20.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 (79.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "LAI treatment during post-phase (N=123)." ] ] 3 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "PDC: proportion of days covered." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Outcome in pre-phase, n (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Outcome in post-phase, n (%)</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">McNemar P-value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adherence (PDC ≥80%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 (22.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (0.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29 (23.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">82 (66.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (9.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">94 (76.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">110 (89.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">13 (10.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">123 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hospitalized relapse</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hospitalized relapse \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 (21.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31 (25.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">57 (46.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.0433 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 (13.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 (39.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">66 (53.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">43 (35.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">80 (65.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">123 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Non-hospitalized relapse</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Non-hospitalized relapse \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (1.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (4.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 (6.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.0039 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (17.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">94 (76.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">115 (93.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23 (18.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100 (81.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">123 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Treatment adherence and patient relapse during pre- and post-phase." ] ] 4 => array:8 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at5" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "ED: emergency department; LoS: length of stay; SD: standard deviation." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pre-phase n (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Post-phase n (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">P-value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of hospitalized relapses</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.89 (1.21) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.54 (0.93) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.0012<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Min-Max \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Overall total hospital LoS (days)<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.2 (21.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.4 (21.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7713<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of relapse symptoms not leading to hospitalization or ED visit</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.07 (0.29) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.25 (0.61) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.0013<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Min-Max \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Wilcoxon signed rank test." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "The number of days for the index hospitalization is divided between the pre-phase (prior to index date) and the post-phase (on or after index date)." ] ] ] "descripcion" => array:1 [ "en" => "Number of hospitalized relapses, total LoS, and non-hospitalized relapses (N=123)." ] ] 5 => array:8 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at6" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "CI: confidence interval; PDC: proportion days covered; PP1M: paliperidone palmitate once monthly; RR: relative risk." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">All patientsN=123 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Continued PP1MN=75 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Discontinued PP1MN=48 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Outcome \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RR (95%CI) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RR (95%CI) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RR (95%CI) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adherence (PDC ≥80%)<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.77 (2.75-5.17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.77 (2.59-5.48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.88 (2.16-6.96) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Relapse<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.76 (0.59-0.99) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.64 (0.42-0.98) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 (0.65-1.25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of relapses<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.61 (0.45-0.83) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.52 (0.33-0.83) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.67 (0.44-1.03) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Relapse symptomsb \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.27 (1.11-4.64) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.15 (0.79-5.81) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.33 (0.95-11.70) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of relapse symptomsb \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.51 (1.16-5.40) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.18 (0.77-6.20) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.95 (1.25-12.48) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "Adjustment variables were illicit substance use (yes/no) and number of psychosocial interventions. bAdjustment variables were illicit substance use (yes/no), number of psychosocial interventions, and number of outpatient psychiatric visits." ] ] ] "descripcion" => array:1 [ "en" => "Conditional Poisson regression for the effect of PP1M initiation on adherence and relapse for all patients, patients who continued and patients who discontinued PP1M during follow-up." ] ] 6 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 71668 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:24 [ 0 => array:3 [ "identificador" => "bib0125" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ministerio de Salud y Protección Social. En Colombia la prevalencia de la esquizofrenia representa el 1% de la población. Published January 10, 2013. Available at: https://www.minsalud.gov.co/Paginas/esquizofrenia-representa-el-1-poblacion.aspx. Accessed August 13, 2019." ] ] ] 1 => array:3 [ "identificador" => "bib0130" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global economic burden of schizophrenia: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.Y. Chong" 1 => "S.L. Teoh" 2 => "D.B.-C. Wu" 3 => "S. Kotirum" 4 => "C.-F. Chiou" 5 => "N. Chaiyakunapruk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/NDT.S96649" "Revista" => array:6 [ "tituloSerie" => "Neuropsychiatr Dis Treat." "fecha" => "2016" "volumen" => "12" "paginaInicial" => "357" "paginaFinal" => "373" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26937191" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0135" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-Term Treatment Goals: Enhancing Healthy Outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D.E. Casey" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1017/S1092852900008178" "Revista" => array:7 [ "tituloSerie" => "CNS Spectr." "fecha" => "2003" "volumen" => "8" "numero" => "Suppl 2" "paginaInicial" => "26" "paginaFinal" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14978456" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0140" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Greene" 1 => "T. Yan" 2 => "E. Chang" 3 => "A. Hartry" 4 => "M. Touya" 5 => "M.S. Broder" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/13696998.2017.1379412" "Revista" => array:6 [ "tituloSerie" => "J Med Econ." "fecha" => "2018" "volumen" => "21" "paginaInicial" => "127" "paginaFinal" => "134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28895758" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0145" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The nature of relapse in schizophrenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Emsley" 1 => "B. Chiliza" 2 => "L. Asmal" 3 => "B.H. Harvey" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-244X-13-50" "Revista" => array:4 [ "tituloSerie" => "BMC Psychiatry." "fecha" => "2013" "volumen" => "13" "paginaInicial" => "50" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0150" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "L. Alphs" 1 => "H.A. Nasrallah" 2 => "C.A. Bossie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/YIC. 0000000000000125" "Revista" => array:6 [ "tituloSerie" => "Int Clin Psychopharmacol." "fecha" => "2016" "volumen" => "31" "paginaInicial" => "202" "paginaFinal" => "209" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26974214" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0155" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral versus Depot Antipsychotic Drugs for Schizophrenia: A Critical Systematic Review and Meta-Analysis of Randomised Long-Term Trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Leucht" 1 => "S. Heres" 2 => "J.M. Kane" 3 => "W. Kissling" 4 => "J.M. Davis" 5 => "S. Leucht" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2011" "editorial" => "Centre for Reviews and Dissemination (UK)" "editorialLocalizacion" => "Lonndon" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0160" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "T. Kishimoto" 1 => "M. Nitta" 2 => "M. Borenstein" 3 => "J.M. Kane" 4 => "C.U. Correll" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4088/JCP.13r08440" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry." "fecha" => "2013" "volumen" => "74" "paginaInicial" => "957" "paginaFinal" => "965" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24229745" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0165" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sistema de Trámites en Línea-Consultas Públicas. Available at: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp. Accessed September 10, 2019." ] ] ] 9 => array:3 [ "identificador" => "bib0170" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Johnson & Johnson. Landmark schizophrenia data that brings hope in breaking the cycle of hospitalization and incarcelation receives FDA approval for inclusion in INVEGA SUSTENNA® (paliperidone palmitate) label. Available at: https://www.jnj.com/media-center/press-releases/landmark-schizophrenia-data-that-brings-hope-in-breaking-the-cycle-of-hospitalization-and-incarceration-receives-fda-approval-for-inclusion-in-invega-sustenna-paliperidone-palmitate-label. Accessed August 29, 2019." ] ] ] 10 => array:3 [ "identificador" => "bib0175" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S.C. Marcus" 1 => "J. Zummo" 2 => "A.R. Pettit" 3 => "J. Stoddard" 4 => "J.A. Doshi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18553/jmcp.2015.21.9.754" "Revista" => array:6 [ "tituloSerie" => "J Manag Care Spec Pharm." "fecha" => "2015" "volumen" => "21" "paginaInicial" => "754" "paginaFinal" => "768" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26308223" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0180" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.D. Vincent" 1 => "M.-F. Demers" 2 => "V. Doyon-Kemp" 3 => "J. Duchesneau" 4 => "A. Halme" 5 => "V. Masson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.schres.2017.01.013" "Revista" => array:6 [ "tituloSerie" => "Schizophr Res." "fecha" => "2017" "volumen" => "185" "paginaInicial" => "96" "paginaFinal" => "100" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28119036" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0185" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EPA-0322—Adherence and Reduction of Admissions in Patients Treated with Paliperidone Palmitate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.M. Gonzalez-Moreno" 1 => "D.G. Castillo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0924-9338(14)77758-2" "Revista" => array:4 [ "tituloSerie" => "Eur Psychiatry." "fecha" => "2014" "volumen" => "29" "numero" => "Suppl 1" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0190" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P. Lefebvre" 1 => "E. Muser" 2 => "K. Joshi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clinthera.2017.05.356" "Revista" => array:6 [ "tituloSerie" => "Clin Ther." "fecha" => "2017" "volumen" => "39" "paginaInicial" => "1380" "paginaFinal" => "1395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28641996" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0195" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Transparencia y Acceso a la Información Pública, Hospital Mental de Antioquia. Available at: http://www.homo.gov.co/transparencia-y-acceso-a-la-informacion-publica. Accessed March 13, 2021." ] ] ] 15 => array:3 [ "identificador" => "bib0200" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. p. 3. Available at: http://www.pqaalliance.org/files/PDCvsMPRfinal.pdf." ] ] ] 16 => array:3 [ "identificador" => "bib0205" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.J. Weiden" 1 => "C. Kozma" 2 => "A. Grogg" 3 => "J. Locklear" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1176/appi.ps.55.8.886" "Revista" => array:5 [ "tituloSerie" => "Psychiatr Serv Wash DC." "fecha" => "2004" "volumen" => "55" "paginaInicial" => "886" "paginaFinal" => "891" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0210" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. DerSarkissian" 1 => "P. Lefebvre" 2 => "K. Joshi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clinthera.2018.07.011" "Revista" => array:6 [ "tituloSerie" => "Clin Ther." "fecha" => "2018" "volumen" => "40" "paginaInicial" => "1496" "paginaFinal" => "1508" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30145029" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0215" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Emond" 1 => "A.C. El Khoury" 2 => "C. Patel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/03007995.2018.1560220" "Revista" => array:6 [ "tituloSerie" => "Curr Med Res Opin." "fecha" => "2019" "volumen" => "35" "paginaInicial" => "407" "paginaFinal" => "416" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30556739" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0220" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "A Study for Schizophrenia Relapse Prediction. Available at: https://clinicaltrials.gov/ct2/show/NCT03629951. Accessed September 10, 2019." ] ] ] 20 => array:3 [ "identificador" => "bib0225" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Janssen Research & Development, LLC. Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Available at: https://clinicaltrials.gov/ct2/show/NCT01662310. Accessed September 12, 2019." ] ] ] 21 => array:3 [ "identificador" => "bib0230" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Forest Laboratories. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia. Available at: https://clinicaltrials.gov/ct2/show/NCT01412060. Accessed September 10, 2019." ] ] ] 22 => array:3 [ "identificador" => "bib0235" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002048-29/SK. Accessed September 10, 2019." ] ] ] 23 => array:3 [ "identificador" => "bib0240" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Risperdal Consta Trial of Relapse Prevention and Effectiveness. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000870-29/HU. Accessed September 10, 2019." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00347450/unassign/S0034745022000622/v1_202208030516/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00347450/unassign/S0034745022000622/v1_202208030516/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745022000622?idApp=UINPBA00004N"]

Statistics

Artículo original

Efectividad Del Palmitato de Paliperidona en la Adherencia al Tratamiento y Las Recaídas en la Población Adulta Con Esquizofrenia: Un estudio en Imagen Especular de un Año en un Centro de salud Mental en Colombia

Oscar Riberoa, Anne-Marie Castillouxb, Lina Maria Agudeloa, Gerardo Machnickic, Vanesa Moralesd, Sergio Peroccoe, Genaro Castillonb, Yola Morideb,f,

Corresponding author

morideyo@ifh.rutgers.edu

Corresponding author.

a E.S.E. Hospital Mental de Antioquia, Bello, Antioquia, Colombia

b YolaRX Consultants, Montreal, Quebec, Canada

c Janssen-Cilag Farmacéutica Ltda., Buenos Aires, Argentina

d Janssen-Cilag S.A., Bogotá, Colombia

e Janssen-Cilag Farmacêutica Ltda., São Paulo, Brazil

f Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States of America

Read

Times
was read the article

Total PDF

Total HTML

Share statistics

 array:22 [
  "pii" => "S0034745022000622"
  "issn" => "00347450"
  "doi" => "10.1016/j.rcp.2022.06.001"
  "estado" => "S200"
  "fechaPublicacion" => "2022-08-03"
  "aid" => "552"
  "copyright" => "Asociaci&#243;n Colombiana de Psiquiatr&#237;a"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S0034745022000853"
    "issn" => "00347450"
    "doi" => "10.1016/j.rcp.2022.07.005"
    "estado" => "S200"
    "fechaPublicacion" => "2022-09-03"
    "aid" => "560"
    "copyright" => "Asociaci&#243;n Colombiana de Psiquiatr&#237;a"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Art&#237;culo original</span>"
      "titulo" => "Prevalencia y factores del trastorno de conducta alimentaria en estudiantes de medicina humana del per&#250; en el contexto de la pandemia de covid-19&#58; estudio multic&#233;ntrico"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Prevalence and Factors Associated with Eating Disorders in Peruvian Human Medicine Students in the Context of the COVID-19 Pandemic&#58; a Multicentre Study"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jean Pierre Zila-Velasque, Pamela Grados-Espinoza, Kateriny Margot Regalado-Rodr&#237;guez, Cesia J&#46; Luna-C&#243;rdova, Gabriela Stefanie Sierra Calder&#243;n, Mills D&#237;az-Vargas, Jhesly Sifuentes-Rosales, Cristian Diaz-V&#233;lez"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "Jean Pierre"
              "apellidos" => "Zila-Velasque"
            ]
            1 => array:2 [
              "nombre" => "Pamela"
              "apellidos" => "Grados-Espinoza"
            ]
            2 => array:2 [
              "nombre" => "Kateriny Margot"
              "apellidos" => "Regalado-Rodr&#237;guez"
            ]
            3 => array:2 [
              "nombre" => "Cesia J&#46;"
              "apellidos" => "Luna-C&#243;rdova"
            ]
            4 => array:2 [
              "nombre" => "Gabriela Stefanie Sierra"
              "apellidos" => "Calder&#243;n"
            ]
            5 => array:2 [
              "nombre" => "Mills"
              "apellidos" => "D&#237;az-Vargas"
            ]
            6 => array:2 [
              "nombre" => "Jhesly"
              "apellidos" => "Sifuentes-Rosales"
            ]
            7 => array:2 [
              "nombre" => "Cristian"
              "apellidos" => "Diaz-V&#233;lez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745022000853?idApp=UINPBA00004N"
    "url" => "/00347450/unassign/S0034745022000853/v1_202209030512/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0034745017300045"
    "issn" => "00347450"
    "doi" => "10.1016/j.rcp.2017.01.003"
    "estado" => "S200"
    "fechaPublicacion" => "2017-02-24"
    "aid" => "196"
    "copyright" => "Asociaci&#243;n Colombiana de Psiquiatr&#237;a"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "ssu"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Art&#237;culo de revisi&#243;n</span>"
      "titulo" => "Alteraciones endocrinas vinculadas a la prescripci&#243;n m&#233;dica de carbonato de litio&#46; Una revisi&#243;n narrativa"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Endocrinological Disorders Related to the Medical Use of Lithium&#46; A Narrative Review"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1444
              "Ancho" => 3179
              "Tamanyo" => 221305
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">L&#237;nea del tiempo para estudios de laboratorio y gabinete<a class="elsevierStyleCrossRefs" href="#bib0745"><span class="elsevierStyleSup">49&#44;50&#44;79&#8211;81</span></a>&#46; Litemia&#58; 1&#46;<span class="elsevierStyleSup">a</span> al mes y trimestralmente las siguientes&#46; A partir de 1&#46;<span class="elsevierStyleSup">er</span>&#160;a&#241;o&#44; semestrales&#46; Estudios de laboratorio y gabinete&#58; protocolos completos en cuadros superiores&#46; 1&#46;<span class="elsevierStyleSup">er</span> a&#241;o&#58; per&#64257;l tiroideo y glucosa&#46; 2&#46;<span class="elsevierStyleSup">o</span> a&#241;o&#58; ultrasonido tiroideo&#46; 3&#46;<span class="elsevierStyleSup">er</span> a&#241;o&#58; protocolo similar al basal&#46; En cualquier momento&#44; realizar los estudios que sean necesarios en correlaci&#243;n con hallazgos cl&#237;nicos&#46; &#42;Los n&#250;meros romanos corresponden a los meses del a&#241;o&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Gerardo Garc&#237;a-Maldonado, Rub&#233;n de Jes&#250;s Castro-Garc&#237;a"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Gerardo"
              "apellidos" => "Garc&#237;a-Maldonado"
            ]
            1 => array:2 [
              "nombre" => "Rub&#233;n de Jes&#250;s"
              "apellidos" => "Castro-Garc&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2530312018300602"
        "doi" => "10.1016/j.rcpeng.2018.12.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530312018300602?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745017300045?idApp=UINPBA00004N"
    "url" => "/00347450/unassign/S0034745017300045/v1_201702240102/es/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Art&#237;culo original</span>"
    "titulo" => "Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population&#58; A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility"
    "tieneTextoCompleto" => true
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Oscar Ribero, Anne-Marie Castilloux, Lina Maria Agudelo, Gerardo Machnicki, Vanesa Morales, Sergio Perocco, Genaro Castillon, Yola Moride"
        "autores" => array:8 [
          0 => array:3 [
            "nombre" => "Oscar"
            "apellidos" => "Ribero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Anne-Marie"
            "apellidos" => "Castilloux"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Lina Maria"
            "apellidos" => "Agudelo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Gerardo"
            "apellidos" => "Machnicki"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Vanesa"
            "apellidos" => "Morales"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Sergio"
            "apellidos" => "Perocco"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Genaro"
            "apellidos" => "Castillon"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          7 => array:4 [
            "nombre" => "Yola"
            "apellidos" => "Moride"
            "email" => array:1 [
              0 => "morideyo@ifh.rutgers.edu"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "E&#46;S&#46;E&#46; Hospital Mental de Antioquia&#44; Bello&#44; Antioquia&#44; Colombia"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "YolaRX Consultants&#44; Montreal&#44; Quebec&#44; Canada"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Janssen-Cilag Farmac&#233;utica Ltda&#46;&#44; Buenos Aires&#44; Argentina"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Janssen-Cilag S&#46;A&#46;&#44; Bogot&#225;&#44; Colombia"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Janssen-Cilag Farmac&#234;utica Ltda&#46;&#44; S&#227;o Paulo&#44; Brazil"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Rutgers&#44; The State University of New Jersey&#44; New Brunswick&#44; New Jersey&#44; United States of America"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Efectividad Del Palmitato de Paliperidona en la Adherencia al Tratamiento y Las Reca&#237;das en la Poblaci&#243;n Adulta Con Esquizofrenia&#58; Un estudio en Imagen Especular de un A&#241;o en un Centro de salud Mental en Colombia"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">In 2013&#44; the Ministry of Health of Colombia reported a prevalence of schizophrenia of 1&#37;&#44; corresponding to about 471&#44;052 people affected by the disease in this country&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">1</span></a> Like elsewhere&#44; prevalence is low but the disease results in a tremendous health&#44; social&#44; and economic burden linked to the early onset of the disease&#44; its incurable nature as well as persisting symptoms&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Antipsychotics are the cornerstone treatment of schizophrenia with the aims of functional rehabilitation&#44; prevention of symptom worsening&#44; enhancement of psychosocial functioning&#44; and improvement of quality of life&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">3</span></a> However&#44; non-adherence to oral antipsychotics &#40;OAPs&#41; ranges between 34&#37; and 81&#37;&#44; which greatly affects their effectiveness in the real-world setting&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">4</span></a> Despite a good response to initial treatment&#44; schizophrenia symptoms often return&#44; which are especially frequent after treatment discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">5</span></a> Consequently&#44; the prevention of relapse is a primary treatment goal for the successful long-term management of schizophrenia&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Long-acting injectable &#40;LAI&#41; formulations have become available to enhance adherence and thereby improve outcomes&#46; According to a meta-analysis of 10 randomized controlled trials &#40;RCTs&#41; published in 2011&#44; LAIs are associated with a lower risk of relapse compared to OAPs &#40;relative risk &#91;RR&#93;<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;70&#59; 95&#37; confidence interval &#91;95&#37;CI&#93;&#44; 0&#46;57-0&#46;87&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">7</span></a> Since then&#44; the benefits of LAIs compared to OAPs have also been shown through observational studies&#44; mainly those that use a mirror-image study design&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">8</span></a> Paliperidone palmitate administered once monthly &#40;PP1M&#41; is one of the LAIs approved for the treatment of schizophrenia&#44;<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">9&#44;10</span></a> and real-world studies have shown that PP1M is associated with significantly fewer inpatient admissions compared to OAPs&#44; mainly due to improved treatment adherence&#46;<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">11&#8211;14</span></a> Because these previous studies have used hospitalization as a measure of relapse&#44; effectiveness of PP1M on a broader manifestation of relapse&#44; such as symptoms not leading to hospitalization&#44; remains poorly examined&#46; Furthermore&#44; there is a paucity of data in the Latin American region on the characteristics of schizophrenia patients treated with PP1M and on its effectiveness on real-world outcomes in this setting&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Our study aimed at evaluating the effectiveness of PP1M on treatment adherence and relapse in the adult schizophrenia population followed in a government-funded mental health care facility with a broad geographical coverage in Bello&#44; Antioquia &#40;Colombia&#41;&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Study design</span><p id="par0025" class="elsevierStylePara elsevierViewall">We conducted a single-arm&#44; non-interventional pre-post comparison &#40;&#8220;mirror-image&#8221;&#41; study to describe the characteristics of adult patients with schizophrenia who initiated PP1M&#44; and to compare treatment adherence and relapse before and after the PP1M initiation&#46; Study was conducted in the inpatient and outpatient settings of E&#46;S&#46;E&#46; Hospital Mental de Antioquia&#44; a 250-bed facility situated in Bello &#40;vicinity of Medellin&#41;&#44; Colombia&#46; There were two retrospective treatment phases&#58; 12 months prior to the first injection of PP1M &#40;pre-phase&#41; and 12 months after the first injection &#40;post-phase&#41;&#46; The date of first injection was referred to as the index date&#46; The study was approved by the research ethics committee at the E&#46;S&#46;E&#46; Hospital Mental de Antioquia&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Data sources</span><p id="par0030" class="elsevierStylePara elsevierViewall">The main data source consisted of secondary use of existing electronic medical records &#40;EMRs&#41; at E&#46;S&#46;E&#46; Hospital Mental de Antioquia&#46; There are approximately 65&#44;000 psychiatric consultations per year at this hospital&#44; and it is estimated that medical records are available for approximately 25&#44;000 psychiatric care patients of all ages&#46;<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">15</span></a> Dispensed medications&#44; including PP1M&#44; OAPs&#44; and concomitant drugs&#44; were obtained through linkage with the hospital pharmacy database&#44; which dispenses the totality of in- and out-patient psychiatric drugs to patients followed at the facility&#46; We ascertained non-hospitalized relapse through the examination of physicians&#8217; notes &#40;narratives&#41; found in the EMRs&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study population</span><p id="par0035" class="elsevierStylePara elsevierViewall">We identified the study population over the period January 1<span class="elsevierStyleSup">st</span>&#44; 2015 to October 31<span class="elsevierStyleSup">st</span>&#44; 2018 in order to have a 12-month pre- and a 12-month post-phase for all study patients &#40;first pre-phase started January 1<span class="elsevierStyleSup">st</span>&#44; 2014 and last post-phase ended October 31<span class="elsevierStyleSup">st</span>&#44; 2019&#41;&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">We included patients who met the following inclusion criteria&#58; <span class="elsevierStyleItalic">a&#41;</span> a confirmed diagnosis of schizophrenia &#40;ICD-10 codes&#58; F20&#46;0 &#91;Paranoid schizophrenia&#93;&#44; F20&#46;1 &#91;Disorganized schizophrenia&#93;&#44; F20&#46;2 &#91;Catatonic schizophrenia&#93;&#44; F20&#46;3 &#91;Undifferentiated schizophrenia&#93;&#44; F20&#46;5 &#91;Residual schizophrenia&#93;&#44; F20&#46;6 &#91;Simple schizophrenia&#93;&#44; F20&#46;8 &#91;Other schizophrenia&#93;&#44; and F20&#46;9 &#91;Schizophrenia&#44; unspecified&#93;&#41; identified at least one year prior to index date&#59; <span class="elsevierStyleItalic">b&#41;</span> to have been prescribed an OAP treatment&#44; regardless of treatment duration and number of products&#44; in pre-phase&#59; <span class="elsevierStyleItalic">c&#41;</span> age &#8805;18 years &#40;adult patients&#41; at first injection of PP1M &#40;index date&#41;&#59; <span class="elsevierStyleItalic">d&#41;</span> to have received an initial dose of &#8805;2 injections of PP1M in a period of one week&#44; regardless of concomitant use of OAPs&#44; treatment duration&#44; and subsequent switches to other LAIs or switch back to OAPs only&#44; and <span class="elsevierStyleItalic">e&#41;</span> to have been followed at the E&#46;S&#46;E&#46; Hospital Mental de Antioquia for at least 12 months prior to&#44; and 12 months after the index date in order to ensure completeness of the EMR&#46; We excluded patients who&#58; <span class="elsevierStyleItalic">a&#41;</span> were diagnosed with refractory schizophrenia&#59; <span class="elsevierStyleItalic">b&#41;</span> used LAIs in pre-phase&#59; <span class="elsevierStyleItalic">c&#41;</span> initiated PP1M in hospital and were never discharged during the following 12 months&#44; and <span class="elsevierStyleItalic">d&#41;</span> died or were lost to follow-up in the post-phase&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Outcomes</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Treatment adherence</span><p id="par0045" class="elsevierStylePara elsevierViewall">We measured treatment adherence using the proportion of days covered &#40;PDC&#41;&#44; defined as the proportion of days with an active antipsychotic drug &#40;total number of days supply&#41; over the entire pre- and post-phase&#44; with the removal of overlapping prescriptions&#46;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">16</span></a> This means that the number of days supply of a drug that is left at the time of switch to a new product is not counted in the PDC calculation&#46; Furthermore&#44; because schizophrenia requires continuous treatment&#44; PDC was calculated in each phase using the entire 365 days as denominator&#46; For OAPs&#44; the total number of days supply was calculated using the dispensing dates and the number of days dispensed&#46; Patient was considered adherent to treatment if PDC was &#8805;80&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">16</span></a> Because the risk of hospitalization increases with every missed day of OAP use&#44;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">17</span></a> no allowance &#40;i&#46;e&#46;&#44; no grace period&#41; was given to assess the number of days with active prescription for OAPs&#46; In accordance with previous published studies&#44; each injection of PP1M was associated with 45 days of active prescription&#46;<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">18&#44;19</span></a> Because of the inclusion criterion of at least two injections in a period of one week&#44; the PDC in the post-phase was calculated starting at 45 days following the second injection&#46; We also conducted a sensitivity analysis&#44; where PP1M was associated with 30 days of active prescription&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">Although hospital-supplied medication during inpatient stay is recorded in the hospital database&#44; adherence is a measure of patient&#39;s behavior&#46; Adherence to OAPs during hospitalization is expected to be 100&#37; and would thus lead to an overestimation of the overall PDC during the 12-month period&#46; Hence&#44; for patients who were hospitalized&#44; the number of days of inpatient stay was not considered for the PDC calculation &#40;neither in the PDC&#39;s numerator or denominator&#41;&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Relapse</span><p id="par0055" class="elsevierStylePara elsevierViewall">Clinically&#44; relapse is defined by the presence of at least one of the following criteria&#58; <span class="elsevierStyleItalic">a&#41;</span> involuntary or voluntary admission to a psychiatric hospital for decompensation of the patient&#39;s schizophrenic symptoms &#40;psychiatric hospitalization or emergency department &#91;ED&#93; visit&#41;&#59; <span class="elsevierStyleItalic">b</span>&#41; suicidal&#47;homicidal ideation judged clinically significant&#59; c&#41; deliberate self-injury&#59; <span class="elsevierStyleItalic">d&#41;</span> clinically meaningful worsening of symptoms as determined by the treating physician&#39;s judgment&#44; and <span class="elsevierStyleItalic">e&#41;</span> violent behavior resulting in clinically significant injury to the patient or another person&#44; or property damage&#46;<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">20&#8211;24</span></a> Hence&#44; we assessed relapse using objective measures of the composite variable of hospitalization or ED visit during the study period &#40;pre- and post-phase&#41; as well as hospital length of stay &#40;LoS&#41;&#46; In addition&#44; we identified relapse symptoms &#40;also referred to as &#8220;relapse signatures&#8221;&#41; through a manual review of clinical notes&#46; Those relapse symptoms not leading to hospitalization or ED visits were then categorized into four categories&#58; suicidal&#47;homicidal ideation&#59; deliberate self-injury&#59; clinically meaningful worsening of symptoms&#59; violent behavior&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">We therefore derived five measures of relapse for each patient and for each phase&#58; <span class="elsevierStyleItalic">a&#41;</span> at least one hospitalized relapse &#40;binary variable&#41;&#59; <span class="elsevierStyleItalic">b&#41;</span> number of hospitalized relapses &#40;count&#41;&#59; <span class="elsevierStyleItalic">c&#41;</span> total hospital LoS&#59; <span class="elsevierStyleItalic">d&#41;</span> at least one occurrence of relapse symptoms not leading to hospitalization or ED visit &#40;binary variable&#41;&#44; and <span class="elsevierStyleItalic">e&#41;</span> number of relapse symptoms not leading to hospitalization or ED visit &#40;count&#41;&#46;</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Potential confounders</span><p id="par0065" class="elsevierStylePara elsevierViewall">Since patients served as their own reference&#44; confounders that remain unchanged over time were controlled for by design&#46; However&#44; we considered as potential confounders variables that vary over time and that may influence the study outcomes &#8212;i&#46;e&#46;&#44; comorbidities&#44; concomitant psychiatric illnesses&#44; alcohol use&#44; tobacco use&#44; illicit drug use&#44; psychosocial interventions&#44; electroconvulsive therapy&#8212; and&#44; for the outcomes of relapse symptoms not leading to hospitalization or ED visit&#44; number of psychiatric outpatient visits &#40;since there would be more opportunity for the detection of relapse symptoms&#41;&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Statistical analyses</span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Comparison of treatment adherence and relapse between pre- and post-phase</span><p id="par0070" class="elsevierStylePara elsevierViewall">We conducted descriptive analyses on patient socio-demographic and clinical characteristics&#44; schizophrenia subtype and number of years since diagnosis&#44; pattern of OAP use in the pre-phase &#40;number and name of OAP products&#41;&#44; status of patient at PP1M initiation &#40;inpatient or outpatient&#41;&#44; reason for PP1M initiation&#44; and discontinuation of PP1M during follow-up &#40;switch to OAP only&#44; or to another LAI with or without OAP&#41;&#46; As these were descriptive analyses&#44; there was no hypothesis-testing&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">We compared frequencies of treatment adherence&#44; hospitalized relapse &#40;dichotomous and count&#41;&#44; total hospital LoS&#44; and non-hospitalized relapse symptoms &#40;dichotomous and count&#41; between the pre- and post-phase&#46; A McNemar test on discordant pairs between pre- and post-phase was used to assess the consistency in adherence&#44; hospitalized relapse&#44; and non-hospitalized relapse&#46; Crude and multivariable conditional Poisson regression models were developed for these outcomes&#46; Confounders that varied over time &#40;described in subsection Potential confounders&#41; were included in the multivariable analyses&#46; We conducted subgroup analyses for patients who continued PP1M and for patients who discontinued &#40;dropped out&#41; during post-phase&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">To account for immortal time bias&#44; we conducted a sensitivity analysis for the outcomes of hospitalized relapse and number of hospitalized relapses&#44; whereby the index hospitalization was excluded from the pre-phase for patients who initiated PP1M in hospital&#46;</p></span></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Results</span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Patient identification flow chart</span><p id="par0085" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#sec0110">Figure 1 in the supplementary material</a> presents the patient selection flow chart for the study&#46; A total of 372 adult patients initiated PP1M at E&#46;S&#46;E&#46; Hospital Mental de Antioquia between January 1<span class="elsevierStyleSup">st</span>&#44; 2015 and October 31<span class="elsevierStyleSup">st</span>&#44; 2018&#44; out of whom 123 &#40;33&#46;1&#37;&#41; were included in the study&#46; Main reason for exclusion was LAI use in the pre-phase &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>180&#44; 48&#46;4&#37;&#41;&#46; There were 54 patients who were lost to follow-up&#44; all for administrative issues such as change of contact information or moving to a different geographical area&#46; There were no death and loss to follow-up was not attributable to treatment failure&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Patient characteristics</span><p id="par0090" class="elsevierStylePara elsevierViewall">As shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#44; most patients were young &#40;mean age&#44; 30&#46;3 years&#41; and males &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>98&#44; 79&#46;7&#37;&#41;&#46; The majority was diagnosed with paranoid schizophrenia &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>74&#44; 60&#46;2&#37;&#41;&#44; followed by other schizophrenia &#40;i&#46;e&#46;&#44; ICD-10 code F20&#46;8&#41;&#46; Most patients initiated PP1M as outpatient &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>86&#44; 69&#46;9&#37;&#41; and poor adherence with OAPs was the primary reason for PP1M initiation for half the patients&#44; followed by a lack of efficacy&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Treatment characteristics</span><p id="par0095" class="elsevierStylePara elsevierViewall">Number and types of OAP used during pre- and post-phase are shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#46; As expected&#44; mean number of OAP products use was higher in the pre-phase than in the post-phase&#44; since it was an inclusion criterion for the study&#46; The most common prescribed OAPs in pre-phase were risperidone and olanzapine while in the post-phase&#44; it was clozapine and olanzapine&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">Discontinuation of PP1M occurred in 48 patients &#40;39&#46;0&#37;&#41;&#44; on average 6 months after initiation&#46; A minority switched to another LAI &#40;pipotiazine palmitate &#91;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>6&#93; and risperidone &#91;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>4&#93;&#41;&#44; with or without use of OAPs&#44; while 29 &#40;60&#46;4&#37;&#41; switched to OAPs only&#46; Details are shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#46; The number of patients who discontinued PP1M did not increase in the sensitivity analysis when considering 30 days of active treatment instead of 45&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Outcomes</span><p id="par0105" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a> presents the number of patients with outcomes in pre- and post-phase&#46; More patients were adherent in the post-phase than in the pre-phase&#44; 110 &#40;89&#46;4&#37;&#41; vs 29 &#40;23&#46;6&#37;&#41;&#46; Results remained the same&#44; whether the number of days of active prescription assigned to each PP1M injection was 45 or 30 in the sensitivity analysis&#46; McNemar test&#44; which tests difference in discordant pre-post pairs&#44; was statistically significant &#40;<span class="elsevierStyleItalic">P</span>&#60;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;0001&#41;&#46; The number of patients with at least one hospitalized relapse decreased from 57 &#40;46&#46;3&#37;&#41; in pre-phase to 43 &#40;35&#46;0&#37;&#41; in post-phase&#46; McNemar test was statistically significant &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;0433&#41;&#46; The only relapse symptom not leading to hospitalization or ED visit reported for this study was &#8220;clinically meaningful worsening of symptoms&#8221;&#46; The number of patients reported as having had this symptom increased in post-phase&#46; McNemar test was statistically significant &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;0039&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0110" class="elsevierStylePara elsevierViewall">As shown in <a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>&#44; the mean number of hospitalized relapses decreased from 0&#46;89<span class="elsevierStyleHsp" style=""></span>&#177; 1&#46;21 in pre-phase to 0&#46;54<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;93 in post-phase &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;0012&#41;&#44; while total hospital LoS decreased from 12&#46;2 to 11&#46;4 days &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;7713&#41;&#46; Conversely&#44; the mean number of non-hospitalized relapse increased from 0&#46;07<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;29 to 0&#46;25<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;61 &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;0013&#41;&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0115" class="elsevierStylePara elsevierViewall">Adjusted relative risks based on conditional Poisson regression&#44; along with 95&#37;CIs&#44; are presented in <a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a> for each outcome&#46; Only potential confounders that changed between pre- and post-phase &#40;i&#46;e&#46;&#44; illicit substance use and number of psychosocial interventions&#41; were included in the multivariable model and interaction was tested between all variables of the model&#46; In addition&#44; for the outcome of relapse symptoms not leading to hospitalization or ED visit&#44; the number of outpatient medical visits was added to the multivariable model&#46; The sensitivity analysis&#44; whereby the index hospitalization was excluded from the pre-phase for those who started PP1M as inpatients&#44; is also presented for the outcomes of hospitalized relapse&#44; number of hospitalized relapses and hospital total LoS&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">Probability of being adherent to any antipsychotic treatment in post-phase was 3&#46;77 times higher than in pre-phase &#40;95&#37; CI&#44; 2&#46;75-5&#46;17&#41;&#46; This probability was similar for patients who continued and for patients who discontinued PP1M in post-phase&#44; as adherence was determined for all treatments combined &#40;PP1M and&#47;or OAPs&#41;&#46; The risk of hospitalized relapse &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;76&#59; 95&#37; CI&#44; 0&#46;59-0&#46;99&#41; and the number of hospitalized relapses &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;61&#59; 95&#37; CI&#44; 0&#46;45-0&#46;83&#41; decreased in post-phase&#46; These decreases were greater in patients who continued PP1M &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;64&#59; 95&#37; CI&#44; 0&#46;42-0&#46;98&#59; and RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;52&#59; 95&#37; CI&#44; 0&#46;33-0&#46;83 respectively&#41; and not significant for patients who discontinued PP1M &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;91&#59; 95&#37; CI&#44; 0&#46;65-1&#46;25&#59; and RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;67&#59; 95&#37; CI&#44; 0&#46;44-1&#46;03 respectively&#41;&#46; In contrast&#44; the risk of relapse symptoms and the number of relapse symptoms increased in post-phase &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&#46;27&#59; 95&#37; CI&#44; 1&#46;11-4&#46;64&#59; and RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&#46;51&#59; 95&#37; CI&#44; 1&#46;16-5&#46;40 respectively&#41;&#44; and these increases were more important for patients who discontinued PP1M &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&#46;33&#59; 95&#37; CI&#44; 0&#46;95-11&#46;70&#59; and RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&#46;95&#59; 95&#37; CI&#44; 1&#46;25-12&#46;48&#44; respectively for relapse symptoms and number of relapse symptoms&#41; than for patients who continued PP1M &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&#46;15&#59; 95&#37;CI&#44; 0&#46;79-5&#46;81&#59; and RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&#46;18&#59; 95&#37; CI&#44; 0&#46;77-6&#46;20&#44; respectively for relapse symptoms and number of relapse symptoms&#41;&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">In the sensitivity analyses&#44; when removing the index hospitalization for patients who started PP1M as inpatients&#44; the risk of hospitalized relapse and the number of hospitalized relapses became statistically nonsignificant between pre- and post-phase &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1&#46;05&#59; 95&#37; CI&#44; 0&#46;79-1&#46;38&#59; and RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;93&#59; 95&#37; CI&#44; 0&#46;67-1&#46;29 respectively&#41;&#46; The results were also statistically nonsignificant for patients who continued PP1M and for those who dropped out&#46; Conversely&#44; the mean hospital LoS in the pre-phase was 9&#46;5 days decreasing to 6&#46;0 days in the post phase &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;017&#41;&#46;</p></span></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Discussion</span><p id="par0130" class="elsevierStylePara elsevierViewall">In this single center study&#44; adherence to OAP prior to the initiation of PP1M was 23&#46;6&#37; using the threshold of 80&#37; of the PDC&#44; which is lower than estimates reported in the literature &#40;34&#37; to 81&#37;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">4</span></a> However&#44; this was to be expected due to the selection of the study population&#46; As this was a mirror-image study&#44; by design all patients initiated PP1M and it was shown that half of these patients initiated PP1M because of poor adherence to OAP&#46; Similar to previous mirror-image studies&#44; PP1M initiation significantly improved treatment adherence&#46; It can therefore be concluded that in patients who are not adherent to OAPs&#44; PP1M initiation greatly improves adherence over a period of one year&#44; even if some patients discontinue the product&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Initiation of PP1M was associated with a RR of 0&#46;76 for hospitalized relapse&#46; Such protective effect is lower than that found in a meta-analysis of six observational studies that included the LAI dropouts &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;44&#59; 95&#37;CI&#44; 0&#46;28-0&#46;67&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">8</span></a> However&#44; in this meta-analysis&#44; estimates were pooled even in the presence of very high statistical heterogeneity between studies &#40;I<span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>&#62;90&#37;&#41;&#46; The magnitude of the reduction in hospitalized relapse found in the current study is nearly the same as that found in a meta-analysis of RCTs &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;7&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">7</span></a> Several studies found in the literature were based on administrative claims data &#40;where symptoms are not documented&#41; while in the hospital EMRs&#44; reasons for hospitalizations are very well documented&#46; Quality of outcome ascertainment may partly explain some of the discrepancies between the effect size found in the current study with those of previous observational studies&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Initiation of PP1M also led to a decrease in the number of hospitalized relapse episodes with a RR of 0&#46;61 &#40;95&#37; CI&#44; 0&#46;45-0&#46;83&#41;&#46; This protective effect is lower than the one previously reported in the meta-analysis of five observational studies that included the LAI dropouts&#44; although it is within the 95&#37; CI of the published estimate &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;42&#59; 95&#37; CI&#44; 0&#46;29-0&#46;63&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">8</span></a> In this meta-analysis&#44; estimates were also pooled even in the presence of very important statistical heterogeneity &#40;I<span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>93&#46;5&#37;&#41;&#46; The beneficial effect of PP1M on the rate of hospitalization disappeared when removing the index hospitalization in the sensitivity analysis&#46; Conversely&#44; decrease in mean LoS became statistically significant&#46; Previous studies have also shown that the removal of the index hospitalization not only affected hospitalization rate but also accentuated the beneficial effect of PP1M on total LoS&#46; It was therefore suggested that PP1M would be more cost-effective when started in an outpatient setting&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">12</span></a> To further elucidate this hypothesis&#44; the effect of PP1M on hospitalization rate and LoS&#44; stratification of findings according to initiation setting &#40;inpatient or outpatient&#41; would need to be conducted&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">Although it is known that treatment discontinuation is highly associated with the worsening of schizophrenia symptoms&#44; there were no studies found in the literature that examined the effect of PP1M initiation on non-hospitalized relapse&#46; Such data gap is mainly due to the absence of qualitative information on clinical symptoms in administrative claims databases&#46; In contrast&#44; symptoms worsening is well documented in the hospital EMRs&#46; Study showed that PP1M initiation resulted in an increase in the proportion of patients with non-hospitalized relapse&#46; This may partly be attributable to the fact that patients who are treated with PP1M must attend the clinic monthly to receive their injection at this hospital&#44; which is accompanied by a medical follow-up visit&#46; Such increase in regular follow-up visits&#44; compared to pre-phase&#44; increases the opportunity for the assessment of relapse symptoms and thus&#44; introduce a detection bias &#40;which is a form of information bias&#41;&#46; It is also common that in time periods between changes in medication&#44; especially antipsychotics&#44; some patients could experience an exacerbation of symptoms of schizophrenia that are not severe enough to initiate hospitalized care&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">Comparing the effect of initiating PP1M on hospitalized and non-hospitalized relapse&#44; one may thus conclude that avoided hospitalizations due to relapse may have contributed to the increase in relapses that were managed in the outpatient setting&#46; Such impact is thus clinically meaningful&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Generalizability of study results is limited to the population who receives mental health services at the E&#46;S&#46;E&#46; Hospital Mental de Antioquia&#46; The eligibility requirement of at least two PP1M injections may introduce selection bias because the start of follow-up predates eligibility&#46; This is a period often labeled as &#8220;immortal time&#8221;&#46; This period&#44; however&#44; was not included in the calculation of adherence&#46; Because it was necessary to allow for a 12-month post-phase period&#44; patients who died or were lost to follow-up during post-phase were not included&#44; and hence&#44; may have overestimated the benefits of PP1M&#46; Nevertheless&#44; loss to follow-up of 54 patients who initiated PP1M was due to administrative issues &#40;e&#46;g&#46;&#44; change of contact information or&#44; moved to a different geographical area&#41;&#46; There were no deaths among these 54 patients&#46; The removal of the index hospitalization in the sensitivity analysis removed the benefits of PP1M on hospitalization rates but accentuated the effect on LoS&#44; which may suggest that the greatest benefits are observed in patients who started PP1M as outpatients&#46; This hypothesis would&#44; however&#44; need further investigation using a larger sample size stratifying by inpatient and outpatient status at PP1M initiation&#46; Due to the absence of a comparison group &#40;i&#46;e&#46;&#44; non-PP1M initiators&#41;&#44; it was not possible to differentiate relapses attributable to the initiation of PP1M from those attributable to the natural history of the disease&#46;</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Conclusions</span><p id="par0160" class="elsevierStylePara elsevierViewall">PP1M initiation led to a dramatic improvement in treatment adherence as well as to a decrease in the occurrence and number of hospitalized relapse episodes&#46; Conversely&#44; there was an increase in the management of relapse symptoms in the outpatient setting&#44; even after taking into account detection bias&#46; This increase could be explained by an improvement in the psychiatric follow-up after PP1M initiation&#46; It is also common that in time periods between changes in medication&#44; especially antipsychotics&#44; some patients could experience an exacerbation of symptoms of schizophrenia that are not severe enough to initiate hospitalized care&#46;</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Funding</span><p id="par0165" class="elsevierStylePara elsevierViewall">This study was funded by McNeill Panama&#46; The funding source was involved in the study design and in the decision to submit the article for publication&#46; The funder had no role in the conduct of the study&#44; i&#46;e&#46;&#44; patient selection&#44; data collection&#44; management&#44; analyses&#44; and interpretation of findings&#46;</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Conflicts of interests</span><p id="par0170" class="elsevierStylePara elsevierViewall">OR is a member of an advisory board and a speaker for Janssen on diseases unrelated to this study&#46; AMC&#44; GC&#44; and YM are employees of YolaRX Consultants&#44; which designed this study&#44; conducted the statistical analyses&#44; interpreted the results&#44; and wrote the manuscript under contractual agreement&#46; LMA has nothing to disclose&#46; GM and VM were employees of Janssen at the time the research was conducted&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1752720"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Introduction"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1543878"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1752721"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Introducci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "M&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1543877"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Materials and methods"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Study design"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Data sources"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Study population"
            ]
            3 => array:3 [
              "identificador" => "sec0030"
              "titulo" => "Outcomes"
              "secciones" => array:2 [
                0 => array:2 [
                  "identificador" => "sec0035"
                  "titulo" => "Treatment adherence"
                ]
                1 => array:2 [
                  "identificador" => "sec0040"
                  "titulo" => "Relapse"
                ]
              ]
            ]
            4 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Potential confounders"
            ]
            5 => array:3 [
              "identificador" => "sec0050"
              "titulo" => "Statistical analyses"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0055"
                  "titulo" => "Comparison of treatment adherence and relapse between pre- and post-phase"
                ]
              ]
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0060"
          "titulo" => "Results"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Patient identification flow chart"
            ]
            1 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Patient characteristics"
            ]
            2 => array:2 [
              "identificador" => "sec0075"
              "titulo" => "Treatment characteristics"
            ]
            3 => array:2 [
              "identificador" => "sec0080"
              "titulo" => "Outcomes"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0085"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0090"
          "titulo" => "Conclusions"
        ]
        9 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "Funding"
        ]
        10 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Conflicts of interests"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-04-12"
    "fechaAceptado" => "2022-06-09"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1543878"
          "palabras" => array:5 [
            0 => "Antipsychotics"
            1 => "Paliperidone palmitate"
            2 => "Schizophrenia"
            3 => "Adherence"
            4 => "Relapse"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1543877"
          "palabras" => array:5 [
            0 => "Antipsic&#243;ticos"
            1 => "Palmitato de paliperidona"
            2 => "Esquizofrenia"
            3 => "Adherencia"
            4 => "Reca&#237;da"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The benefits of long-acting injectable antipsychotics have been documented in several observational studies&#44; but data remain scarce in Latin America&#46; This study aimed at evaluating the effectiveness of paliperidone palmitate once monthly &#40;PP1M&#41; on treatment adherence and relapse in the schizophrenia population followed in a government-funded mental health care facility in Colombia&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A mirror-image study was conducted&#46; Adult schizophrenia patients treated with oral antipsychotics who subsequently received &#8805;2 PP1M injections between Jan&#46; 1<span class="elsevierStyleSup">st</span>&#44; 2015 and Oct&#46; 31<span class="elsevierStyleSup">st</span>&#44; 2018 were included&#46; The study consisted of two retrospective phases&#58; 12 months before and after the first PP1M injection&#46; Outcomes were treatment adherence &#40;proportion of days covered &#8805;80&#37;&#41;&#44; hospitalized relapse&#44; hospital length of stay&#44; and non-hospitalised relapse&#46; Effect of PP1M on outcomes was assessed through multivariable conditional Poisson regression&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">123 patients were eligible &#40;mean age&#44; 30&#46;3 years&#59; 79&#46;7&#37; males&#41;&#46; Adherence was 23&#46;6&#37; in the pre-phase and 89&#46;4&#37; in the post-phase &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&#46;77&#59; 95&#37;CI&#44; 2&#46;75-5&#46;17&#41;&#46; The proportion of patients with hospitalised relapse decreased from 46&#46;3&#37; to 35&#46;0&#37; &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;76&#59; 95&#37;CI&#44; 0&#46;59-0&#46;99&#41;&#46; In the 75 &#40;61&#46;0&#37;&#41; patients who continued PP1M throughout post-phase&#44; beneficial effect on hospitalised relapse was stronger &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;64&#59; 95&#37;CI&#44; 0&#46;42-0&#46;98&#41;&#46; The proportion of patients with non-hospitalised relapse symptoms increased from 6&#46;5&#37; to 18&#46;7&#37; &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&#46;27&#59; 95&#37;CI&#44; 1&#46;11-4&#46;64&#41;&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">PP1M initiation led to a dramatic improvement in treatment adherence and a decrease in hospitalised relapse&#46; Observed increase in non-hospitalised relapse may be explained by a decrease in severity&#46; Limitations are absence of a parallel comparison group and a generalisability limited to the population treated at this facility&#46; Study provides data for the Latin America region and strength is the assessment of non-hospitalised relapse symptoms&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Introduction"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducci&#243;n</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Los beneficios de los antipsic&#243;ticos inyectables de acci&#243;n prolongada se han documentado en varios estudios observacionales&#44; pero los datos de Am&#233;rica Latina siguen siendo escasos&#46; El estudio se dirige a evaluar la efectividad del palmitato de paliperidona 1 vez al mes &#40;PP1M&#41; en la adherencia al tratamiento y las reca&#237;das en la poblaci&#243;n con esquizofrenia seguida en un centro p&#250;blico de salud mental en Colombia&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">M&#233;todos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se realiz&#243; un estudio en imagen especular&#46; Se incluy&#243; a pacientes adultos con esquizofrenia tratados con antipsic&#243;ticos orales que posteriormente recibieron<span class="elsevierStyleHsp" style=""></span>&#62; 2 PP1M entre el 1 de enero de 2015 y el 31 de octubre de 2018&#46; El estudio consisti&#243; en 2 fases retrospectivas&#58; 12 meses antes y despu&#233;s de la primera inyecci&#243;n de PP1M&#46; Se evalu&#243; la adherencia al tratamiento &#40;proporci&#243;n de d&#237;as cubiertos &#8805; 80&#37;&#41;&#44; la reca&#237;da hospitalizada&#44; la duraci&#243;n de la estancia hospitalaria y la reca&#237;da no hospitalizada&#46; El efecto del PP1M se evalu&#243; mediante la regresi&#243;n de Poisson&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Fueron elegibles 123 pacientes &#40;media de edad&#44; 30&#44;3 a&#241;os&#59; el 79&#44;7&#37; varones&#41;&#46; La adherencia fue del 23&#44;6&#37; en la fase previa y del 89&#44;4&#37; en la segunda &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&#44;77&#59; IC95&#37;&#44; 2&#44;75-5&#44;17&#41;&#46; La proporci&#243;n de pacientes con reca&#237;da hospitalizada disminuy&#243; del 46&#44;3 al 35&#44;0&#37; &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;76&#59; IC95&#37;&#44; 0&#44;59-0&#44;99&#41;&#46; De los 75 pacientes &#40;61&#44;0&#37;&#41; que continuaron PP1M en la segunda fase&#44; el efecto beneficioso en la reca&#237;da hospitalizada fue m&#225;s fuerte &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;64&#59; IC95&#37;&#44; 0&#44;42-0&#44;98&#41;&#46; La proporci&#243;n de pacientes con s&#237;ntomas de reca&#237;da no hospitalizados aument&#243; del 6&#44;5 al 18&#44;7&#37; &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&#44;27&#59; IC95&#37;&#44; 1&#44;11-4&#44;64&#41;&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">La iniciaci&#243;n de PP1M llev&#243; a una dr&#225;stica mejora en la adherencia al tratamiento y a una disminuci&#243;n de la reca&#237;da hospitalizada&#46; El aumento observado en la reca&#237;da no hospitalizada puede explicarse por una disminuci&#243;n de la gravedad&#46; Las limitaciones son la ausencia de un grupo de comparaci&#243;n paralelo y que la generalizabilidad se limita a la poblaci&#243;n tratada en este centro&#46; La fortaleza del estudio es la presentaci&#243;n de datos de la regi&#243;n de Am&#233;rica Latina y la evaluaci&#243;n de s&#237;ntomas de reca&#237;da no hospitalizada&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Introducci&#243;n"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "M&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0180" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Supplementary data"
            "identificador" => "sec0110"
          ]
        ]
      ]
    ]
    "multimedia" => array:7 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">ICD-10&#58; International Classification of Diseases 10<span class="elsevierStyleSup">th</span> Revision&#59; OAP&#58; oral antipsychotic&#59; PP1M&#58; paliperidone palmitate once monthly&#59; SD&#58; standard deviation&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>123&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Age &#40;years&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;3 &#40;10&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Min-Max&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18-60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sex&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;20&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">98 &#40;79&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Schizophrenia ICD-10 subtype&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Paranoid schizophrenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74 &#40;60&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Other schizophrenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;39&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Residual schizophrenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;0&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Patient status at PP1M initiation&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Outpatient&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">86 &#40;69&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inpatient&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;30&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Primary reason for PP1M initiation&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Adherence issue with OAPs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">62 &#40;50&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Lack of efficacy of OAPs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44 &#40;35&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Patient preference&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;5&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tolerance issue&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;4&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Other&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Patient socio-demographic and clinical characteristics&#44; patient status at index date&#44; and primary reason for PP1M initiation&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">OAP&#58; oral antipsychotic&#59; SD&#58; standard deviation&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>123</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pre-phase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Post-phase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Number of OAP products use&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;8 &#40;0&#46;90&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;5 &#40;0&#46;83&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Min-Max&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Type of OAP use&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Risperidone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">68 &#40;55&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">43 &#40;35&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Olanzapine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57 &#40;46&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50 &#40;40&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Clozapine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40 &#40;32&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51 &#40;41&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Paliperidone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 &#40;19&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Other&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;27&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32 &#40;26&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">OAP treatment during pre- and post-phase&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">LAI&#58; long-acting injectable&#59; OAP&#58; oral antipsychotic&#59; PP1M&#58; paliperidone palmitate once monthly&#59; SD&#58; standard deviation&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">PP1M discontinuation&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;39&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">75 &#40;61&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Time to PP1M discontinuation &#40;days&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">186&#46;9 &#40;113&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">147&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Min-Max&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">53-360&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Switch back to OAP only&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29 &#40;60&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19 &#40;39&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Switch to another LAI&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;20&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">38 &#40;79&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">LAI treatment during post-phase &#40;N<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>123&#41;&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">PDC&#58; proportion of days covered&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Outcome in pre-phase&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="3" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Outcome in post-phase&#44; n &#40;&#37;&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">McNemar <span class="elsevierStyleItalic">P</span>-value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Adherence &#40;PDC &#8805;80&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28 &#40;22&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;0&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29 &#40;23&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">0</span>&#46;0001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">82 &#40;66&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;9&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">94 &#40;76&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleHsp" style=""></span>Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">110 &#40;89&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">13 &#40;10&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">123&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="5" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hospitalized relapse</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hospitalized relapse</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;21&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;25&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57 &#40;46&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;0433&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;13&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49 &#40;39&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">66 &#40;53&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleHsp" style=""></span>Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">43 &#40;35&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">80 &#40;65&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">123&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="5" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Non-hospitalized relapse</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Non-hospitalized relapse</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;1&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;4&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;6&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;0039&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;17&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">94 &#40;76&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">115 &#40;93&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;18&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100 &#40;81&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">123&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Treatment adherence and patient relapse during pre- and post-phase&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">ED&#58; emergency department&#59; LoS&#58; length of stay&#59; SD&#58; standard deviation&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pre-phase n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Post-phase n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span>-value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Number of hospitalized relapses</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;89 &#40;1&#46;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;54 &#40;0&#46;93&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;0012<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Min-Max&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Overall total hospital LoS &#40;days&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&#46;2 &#40;21&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&#46;4 &#40;21&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;7713<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Number of relapse symptoms not leading to hospitalization or ED visit</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;07 &#40;0&#46;29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;25 &#40;0&#46;61&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;0013<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Min-Max&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Wilcoxon signed rank test&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">The number of days for the index hospitalization is divided between the pre-phase &#40;prior to index date&#41; and the post-phase &#40;on or after index date&#41;&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Number of hospitalized relapses&#44; total LoS&#44; and non-hospitalized relapses &#40;N<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>123&#41;&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at6"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">CI&#58; confidence interval&#59; PDC&#58; proportion days covered&#59; PP1M&#58; paliperidone palmitate once monthly&#59; RR&#58; relative risk&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">All patientsN<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>123&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Continued PP1MN<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Discontinued PP1MN<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>48&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RR &#40;95&#37;CI&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RR &#40;95&#37;CI&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RR &#40;95&#37;CI&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Adherence &#40;PDC &#8805;80&#37;&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;77 &#40;2&#46;75-5&#46;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;77 &#40;2&#46;59-5&#46;48&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;88 &#40;2&#46;16-6&#46;96&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Relapse<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;76 &#40;0&#46;59-0&#46;99&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;64 &#40;0&#46;42-0&#46;98&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;91 &#40;0&#46;65-1&#46;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Number of relapses<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;61 &#40;0&#46;45-0&#46;83&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;52 &#40;0&#46;33-0&#46;83&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;67 &#40;0&#46;44-1&#46;03&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Relapse symptoms<span class="elsevierStyleSup">b</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;27 &#40;1&#46;11-4&#46;64&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;15 &#40;0&#46;79-5&#46;81&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;33 &#40;0&#46;95-11&#46;70&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Number of relapse symptoms<span class="elsevierStyleSup">b</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;51 &#40;1&#46;16-5&#46;40&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;18 &#40;0&#46;77-6&#46;20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;95 &#40;1&#46;25-12&#46;48&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Adjustment variables were illicit substance use &#40;yes&#47;no&#41; and number of psychosocial interventions&#46;</p> <p class="elsevierStyleNotepara" id="npar0020"><span class="elsevierStyleSup">b</span>Adjustment variables were illicit substance use &#40;yes&#47;no&#41;&#44; number of psychosocial interventions&#44; and number of outpatient psychiatric visits&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Conditional Poisson regression for the effect of PP1M initiation on adherence and relapse for all patients&#44; patients who continued and patients who discontinued PP1M during follow-up&#46;</p>"
        ]
      ]
      6 => array:5 [
        "identificador" => "upi0005"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.pdf"
          "ficheroTamanyo" => 71668
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:24 [
            0 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ministerio de Salud y Protecci&#243;n Social&#46; En Colombia la prevalencia de la esquizofrenia representa el 1&#37; de la poblaci&#243;n&#46; Published January 10&#44; 2013&#46; Available at&#58; https&#58;&#47;&#47;www&#46;minsalud&#46;gov&#46;co&#47;Paginas&#47;esquizofrenia-representa-el-1-poblacion&#46;aspx&#46; Accessed August 13&#44; 2019&#46;"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global economic burden of schizophrenia&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "H&#46;Y&#46; Chong"
                            1 => "S&#46;L&#46; Teoh"
                            2 => "D&#46;B&#46;-C&#46; Wu"
                            3 => "S&#46; Kotirum"
                            4 => "C&#46;-F&#46; Chiou"
                            5 => "N&#46; Chaiyakunapruk"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/NDT.S96649"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neuropsychiatr Dis Treat&#46;"
                        "fecha" => "2016"
                        "volumen" => "12"
                        "paginaInicial" => "357"
                        "paginaFinal" => "373"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26937191"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-Term Treatment Goals&#58; Enhancing Healthy Outcomes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "D&#46;E&#46; Casey"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1017/S1092852900008178"
                      "Revista" => array:7 [
                        "tituloSerie" => "CNS Spectr&#46;"
                        "fecha" => "2003"
                        "volumen" => "8"
                        "numero" => "Suppl 2"
                        "paginaInicial" => "26"
                        "paginaFinal" => "28"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14978456"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Greene"
                            1 => "T&#46; Yan"
                            2 => "E&#46; Chang"
                            3 => "A&#46; Hartry"
                            4 => "M&#46; Touya"
                            5 => "M&#46;S&#46; Broder"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13696998.2017.1379412"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Med Econ&#46;"
                        "fecha" => "2018"
                        "volumen" => "21"
                        "paginaInicial" => "127"
                        "paginaFinal" => "134"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28895758"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The nature of relapse in schizophrenia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "R&#46; Emsley"
                            1 => "B&#46; Chiliza"
                            2 => "L&#46; Asmal"
                            3 => "B&#46;H&#46; Harvey"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-244X-13-50"
                      "Revista" => array:4 [
                        "tituloSerie" => "BMC Psychiatry&#46;"
                        "fecha" => "2013"
                        "volumen" => "13"
                        "paginaInicial" => "50"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "L&#46; Alphs"
                            1 => "H&#46;A&#46; Nasrallah"
                            2 => "C&#46;A&#46; Bossie"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/YIC. 0000000000000125"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Clin Psychopharmacol&#46;"
                        "fecha" => "2016"
                        "volumen" => "31"
                        "paginaInicial" => "202"
                        "paginaFinal" => "209"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26974214"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral versus Depot Antipsychotic Drugs for Schizophrenia&#58; A Critical Systematic Review and Meta-Analysis of Randomised Long-Term Trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46; Leucht"
                            1 => "S&#46; Heres"
                            2 => "J&#46;M&#46; Kane"
                            3 => "W&#46; Kissling"
                            4 => "J&#46;M&#46; Davis"
                            5 => "S&#46; Leucht"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2011"
                        "editorial" => "Centre for Reviews and Dissemination &#40;UK&#41;"
                        "editorialLocalizacion" => "Lonndon"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-acting injectable versus oral antipsychotics in schizophrenia&#58; a systematic review and meta-analysis of mirror-image studies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "T&#46; Kishimoto"
                            1 => "M&#46; Nitta"
                            2 => "M&#46; Borenstein"
                            3 => "J&#46;M&#46; Kane"
                            4 => "C&#46;U&#46; Correll"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4088/JCP.13r08440"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Psychiatry&#46;"
                        "fecha" => "2013"
                        "volumen" => "74"
                        "paginaInicial" => "957"
                        "paginaFinal" => "965"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24229745"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Sistema de Tr&#225;mites en L&#237;nea-Consultas P&#250;blicas&#46; Available at&#58; http&#58;&#47;&#47;consultaregistro&#46;invima&#46;gov&#46;co&#58;8082&#47;Consultas&#47;consultas&#47;consreg&#95;encabcum&#46;jsp&#46; Accessed September 10&#44; 2019&#46;"
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Johnson &#38; Johnson&#46; Landmark schizophrenia data that brings hope in breaking the cycle of hospitalization and incarcelation receives FDA approval for inclusion in INVEGA SUSTENNA&#174; &#40;paliperidone palmitate&#41; label&#46; Available at&#58; https&#58;&#47;&#47;www&#46;jnj&#46;com&#47;media-center&#47;press-releases&#47;landmark-schizophrenia-data-that-brings-hope-in-breaking-the-cycle-of-hospitalization-and-incarceration-receives-fda-approval-for-inclusion-in-invega-sustenna-paliperidone-palmitate-label&#46; Accessed August 29&#44; 2019&#46;"
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;C&#46; Marcus"
                            1 => "J&#46; Zummo"
                            2 => "A&#46;R&#46; Pettit"
                            3 => "J&#46; Stoddard"
                            4 => "J&#46;A&#46; Doshi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.18553/jmcp.2015.21.9.754"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Manag Care Spec Pharm&#46;"
                        "fecha" => "2015"
                        "volumen" => "21"
                        "paginaInicial" => "754"
                        "paginaFinal" => "768"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26308223"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "P&#46;D&#46; Vincent"
                            1 => "M&#46;-F&#46; Demers"
                            2 => "V&#46; Doyon-Kemp"
                            3 => "J&#46; Duchesneau"
                            4 => "A&#46; Halme"
                            5 => "V&#46; Masson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.schres.2017.01.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Schizophr Res&#46;"
                        "fecha" => "2017"
                        "volumen" => "185"
                        "paginaInicial" => "96"
                        "paginaFinal" => "100"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28119036"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EPA-0322&#8212;Adherence and Reduction of Admissions in Patients Treated with Paliperidone Palmitate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;M&#46; Gonzalez-Moreno"
                            1 => "D&#46;G&#46; Castillo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0924-9338(14)77758-2"
                      "Revista" => array:4 [
                        "tituloSerie" => "Eur Psychiatry&#46;"
                        "fecha" => "2014"
                        "volumen" => "29"
                        "numero" => "Suppl 1"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46; Lefebvre"
                            1 => "E&#46; Muser"
                            2 => "K&#46; Joshi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clinthera.2017.05.356"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Ther&#46;"
                        "fecha" => "2017"
                        "volumen" => "39"
                        "paginaInicial" => "1380"
                        "paginaFinal" => "1395"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28641996"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Transparencia y Acceso a la Informaci&#243;n P&#250;blica&#44; Hospital Mental de Antioquia&#46; Available at&#58; http&#58;&#47;&#47;www&#46;homo&#46;gov&#46;co&#47;transparencia-y-acceso-a-la-informacion-publica&#46; Accessed March 13&#44; 2021&#46;"
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Nau DP&#46; Proportion of Days Covered &#40;PDC&#41; as a Preferred Method of Measuring Medication Adherence&#46; p&#46; 3&#46; Available at&#58; http&#58;&#47;&#47;www&#46;pqaalliance&#46;org&#47;files&#47;PDCvsMPRfinal&#46;pdf&#46;"
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "P&#46;J&#46; Weiden"
                            1 => "C&#46; Kozma"
                            2 => "A&#46; Grogg"
                            3 => "J&#46; Locklear"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1176/appi.ps.55.8.886"
                      "Revista" => array:5 [
                        "tituloSerie" => "Psychiatr Serv Wash DC&#46;"
                        "fecha" => "2004"
                        "volumen" => "55"
                        "paginaInicial" => "886"
                        "paginaFinal" => "891"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46; DerSarkissian"
                            1 => "P&#46; Lefebvre"
                            2 => "K&#46; Joshi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clinthera.2018.07.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Ther&#46;"
                        "fecha" => "2018"
                        "volumen" => "40"
                        "paginaInicial" => "1496"
                        "paginaFinal" => "1508"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30145029"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "B&#46; Emond"
                            1 => "A&#46;C&#46; El Khoury"
                            2 => "C&#46; Patel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/03007995.2018.1560220"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Med Res Opin&#46;"
                        "fecha" => "2019"
                        "volumen" => "35"
                        "paginaInicial" => "407"
                        "paginaFinal" => "416"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30556739"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "A Study for Schizophrenia Relapse Prediction&#46; Available at&#58; https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT03629951&#46; Accessed September 10&#44; 2019&#46;"
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Janssen Research &#38; Development&#44; LLC&#46; Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia&#58; A Randomized&#44; Double-Blind&#44; Placebo-Controlled&#44; Parallel-Group Study&#46; Available at&#58; https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT01662310&#46; Accessed September 12&#44; 2019&#46;"
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Forest Laboratories&#46; A Randomized&#44; Double-Blind&#44; Placebo-Controlled&#44; Parallel-Group Study of Cariprazine &#40;RGH-188&#41; in the Prevention of Relapse in Patients With Schizophrenia&#46; Available at&#58; https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT01412060&#46; Accessed September 10&#44; 2019&#46;"
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "A randomized&#44; double-blind&#44; placebo-controlled&#44; parallel-group study of cariprazine &#40;RGH-188&#41; in the prevention of relapse in patients with schizophrenia&#46; Available at&#58; https&#58;&#47;&#47;www&#46;clinicaltrialsregister&#46;eu&#47;ctr-search&#47;trial&#47;2011-002048-29&#47;SK&#46; Accessed September 10&#44; 2019&#46;"
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Risperdal Consta Trial of Relapse Prevention and Effectiveness&#46; Available at&#58; https&#58;&#47;&#47;www&#46;clinicaltrialsregister&#46;eu&#47;ctr-search&#47;trial&#47;2004-000870-29&#47;HU&#46; Accessed September 10&#44; 2019&#46;"
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00347450/unassign/S0034745022000622/v1_202208030516/en/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/00347450/unassign/S0034745022000622/v1_202208030516/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745022000622?idApp=UINPBA00004N"
]

Article information

ISSN: 00347450
Original language: English

DOI:10.1016/j.rcp.2022.06.001

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 April	1	0	1
2023 November	4	0	4
2023 March	0	2	2

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter